research grants 2014-2015

Transcription

NAME
AGENCY
JGH Totals (External grants & career awards)
Medicine Totals (External grants & career awards)
Medicine - Totals
Students
Operating Grants & Awards
AFILALO, Jonathan
AFILALO, Jonathan
Fondation des maladies du coeur
du Canada (FMCC)
Fonds de la recherche en santé du
Québec (FRSQ)
AFILALO, Jonathan
Québec (FRSQ)
AFILALO, Jonathan
Québec (FRSQ)
AFILALO, Jonathan
Instituts de recherche en santé du
Canada (IRSC)
Québec (FRSQ)
AFILALO, Marc
Morand, Grégoire
AFILALO, Marc
AGULNIK, Jason
ALAOUI-JAMALI, Moulay
Merchavy, Shlomo
Morand, Grégoire
Alkailani, Maisa Ismael GH
Alkailani, Maisa Ismael GH
ASSOULINE, Sarit
CHU, Tsz Wai
MANCINI, Johanna
MacNeil, Deanna
MANCINI, Johanna
CHU, Tsz Wai
AUTEXIER, Chantal
AUTEXIER, Chantal
AUTEXIER, Chantal
AUTEXIER, Chantal
AUTEXIER, Chantal
GOLABI, Nahid
AUTEXIER, Chantal
AUTEXIER, Chantal
AUTEXIER, Chantal
AUTEXIER, Chantal
AUTEXIER, Chantal
GRANTS AND BURSARIES
APRIL 1, 2014 - MARCH 31, 2015
TITLE
Regroupement de particuliers
Jewish Hospital Foundation
Recherche suisse contre le cancer
(RSC)
Crown Family Philanthropies
Recherche suisse contre le cancer
(RSC)
Qatar National Research Fund
(QNRF)
Qatar National Research Fund
(QNRF)
Fondation du cancer du sein du
Québec
Measurements of frailty to identify high-risk elderly patients referred for
surgical and transcatheter aortic valve replacement.
Mesure de la fragilité pour identifier les patients âgés à haut risque de
complications après un remplacement valvulaire aortique chirurgical ou
percutané
percutané
percutané
Measurement of frailty to identify high-risk elderly patients referred for
surgical and transcatheter aortic valve replacement
Utilisation des services médicaux d'urgence et hospitaliers chez la
clientèle âgée de 75 ans et plus : Quel est l'impact de l'accès aux
ressources médicales et communautaires de première ligne ?
Emergency Department Research.
LunGevity Pulmonary Oncology Research.
Identifying novel markers of oral cancer progression.
External Grants Career Awards
39,075,596
27,568,152
27,568,152
Clinical
Research
Awards
5,124,688
4,174,821
4,174,821
188,000
188,000
11,126
22,778
1,236
7,527
91,626
1,598
510,706
90,317
5,806
Research of exosomes in tongue cancer.
Identifying novel markers of oral cancer progression.
Investigation of Novel Therapeutic Targets for Inflammatory Breast
Cancer
Investigation of Novel Therapeutic Targets for Inflammatory Breast
Cancer
Études précliniques de molécules anti-métastatiques capables de reprogrammer des cellules invasives du cancer du sein exprimant des
marquers EMT/cellules souches.
Société de recherche sur le
Optimization of novel therapeutic approach targeting breast cancer cell
canacer Inc
plasticity and epithelial-to-mesenchymal transition for metastatic breast
cancer.
Instituts de recherche en santé du Investigation of the filamin signaling network's function in cancer
Canada (IRSC)
progression.
Fonds de la recherche en santé du Des interventions pharmacologiques innovantes ciblant la transcription
Québec (FRSQ)
et la traduction génique entraîneront des réponses significatives dans le
traitement des tumeurs lympho-myéloïdes malignes : proposition de
deux essais cliniques, qui font le pont entr
Université McGill
Characterization of the insertion finger domain of telomerase.
Fondation Cole
Telomerase associated proteins
Université McGill
Telomerase regulation by sumoylation.
Fondation Cole
Telomerase associated proteins
Fonds de la recherche en santé du Charactérisation d'un domaine unique (Insertion in Fingers Domain) de
Québec (FRSQ)
la transcriptase inverse télomérase dans le maintient des télomères, la
survie cellulaire et son implication dans la maladie de la dyskératose
congénitale.
Fonds de la recherche en santé du Caractérisation des mécanismes controllant la recombinaison
Québec (FRSQ)
télomérique et la survie des cellules cancéreuses
Instituts de recherche en santé du 2nd Canadian Symposium on Telomeres and Genome Integrity
Canada (IRSC)
Institut de recherche de la Société A haploid genetic screen in human cells to identify genes regulating
canadienne du Cancer (IRSCC)
chromosome end protection.
Université McGill
Telomerase regulation.
Instituts de recherche en santé du Telomerase regulation.
Canada (IRSC)
5,743,324
2,927,850
2,927,850
Industrial
Contracts
20,604
24,153
50,545
55,861
30,907
112,912
140,132
8,940
956
5,440
8,154
16,560
18,407
20,000
3,813
16,209
32,212
133,429
1
BARON, Murray
Regroupement de compagnies,
corporations
BARON, Murray
fondations et particuliers (Canada)
BATIST, Gerald
Québec (FRSQ)
Sir Mortimer B. Davis - Hôpital
Général Juif
Princess Margaret Hospital
Foundation (The)
Research Foundation Sir Mortimer
B. Davis, Jewish General Hospital
Hoffmann-La Roche Limitée,
Canada
Canada (IRSC)
Consortium de recherche en
oncologie clinique (Q-CROC)
Génome Québec
Institut de recherche Terry Fox
(IRTF)
Fonds de recherche du Québec Société et culture (FRQSC)
École nationale d'administration
publique (ÉNAP)
National Center for Geriatrics and
Gerontology (The) (NCGG)
Canada (IRSC)
Canada (IRSC)
Université de Montréal
BATIST, Gerald
BATIST, Gerald
BATIST, Gerald
BATIST, Gerald
BATIST, Gerald
BATIST, Gerald
BATIST, Gerald
BATIST, Gerald
BATIST, Gerald
NEGOITA, Bogdan
BATIST, Gerald
BELAND, François
Lepage, Annick
BELAND, François
Tsujimoto, Masashi
BELAND, François
BELAND, François
BELAND, François
BELAND, François
BERGMAN, Howard
BERGMAN, Howard
BERGMAN, Howard
BERGMAN, Howard
BERGMAN, Howard
MEHDI, Tahiri
BERGMAN, Simon
BERGMAN, Simon
BERGMAN, Simon
BERGMAN, Simon
BERGMAN, Simon
BERGMAN, Simon
Saliba, James
BLANK, Volker
DODARD-FRIEDMAN, Isadore
KANNAN, Meenakshi Bhairavi
BLANK, Volker
BLANK, Volker
Canada (IRSC)
Fonds de recherche du Québec Santé (FRQS)
Canada (IRSC)
Canada (IRSC)
Canada (IRSC)
Université McGill
56,170
A multicenter, open label study to describe the safety of daily
subcutaneous injections of Anakinar (r-metHuIL-1ra) in patients with
rheumatoid arthritis.
Canadian Scleroderma Research Group.
60,450
Axe thérapies expérimentales / Réseau de recherche sur le cancer
3,163
2009 Ride to Conquer Cancer
21,000
Ride 2009, 2010 Royalty Collaborative Research.
35,000
Segal Research Coordination
100,000
WINTHER Trial - WIN (Worldwid Innovative Network: For Personalized
Medicine.
Novel strategy to selectively target tumor cell growth and
chemosensitivity.
Translational Research Center.
(Q-CROC-01) - PMPC - Projet mobilisateur: Partenariat pour la
médicine personnalisée en cancer du Québec.
Réseau en soins de santé personnalisés Q-CROC.
Pan-Canadian colorectal cancer consortium (C4) - phase I.
100,000
Oncology Research.
Technology use and knowledge transfer.
L'évolution conjointe du professionnalisme et de l'organisation des
soins dans le contexte du Centre Segal sur le cancer.
The methodology comparison of longitudinal study between Canada
and Japan.
Veillissement et les maladies chroniques de RUIS McGill (Réseau
Universitaire Intégré de Santé McGill).
Canadian Longitudinal Study on Aging (CLSA) - Mobility Initiative (CMI) An Emerging Team in Mobility in Aging
Évaluation des interventions individuelles et sociétales pour promouvoir
le vieillissement actif
Canadian Longitudinal Study on Aging (CLSA) - Mobility Initiative (CMI) An Emerging Team in Mobility in Aging
Plan d'action ministériel sur les troubles cognitifs liés au vieillissement:
une évaluation de l'implantation et des résultats des projets initiaux en
vue d'une généralisation progressive au Québec.
Assessing care models implemented in primary health care for persons
with Alzheimer's disease and related disorders
Canadian Longitudinal Study on Aging (CLSA) ou Étude longitudinale
canadienne sur le vieillissement (ELCV)
suite du projet 41901
Canadian Consortium on Neurodegeneration in Aging - Full Proposal
Understanding surgical recovery in elderly patients and its association
with quality care.
Fonds de la recherche en santé du Optimisation de la qualité des soins et du rétablissement chirurgical
Québec (FRSQ)
chez les personnes âgées
Research Foundation Sir Mortimer Surgical research.
Hôpital Saint Mary's, Montréal
Understanding the association between perioperative recovery processbased quality indicators and surgical recovery in the elderly.
Instituts de recherche en santé du Assessing care models implemented in primary health care for persons
Canada (IRSC)
Instituts de recherche en santé du Understanding surgical recovery in elderly patients and its association
Canada (IRSC)
with quality of care.
Société d'entreprise et de gestion Role of CNC and Maf transcription in mammalian gene regulation,
(SEG) (Liban)
stress response and tumorigenesis.
Université McGill
The role of the NFE2L3 transcription factor in breast cancer.
Université McGill
Role of Nrf3 transcription factor in carcinogenesis.
153,556
157,368
645,967
721,052
1,101,794
1,765,807
797
4,368
8,820
284
371
696
1,238
9,693
45,499
65,300
194,964
15,055
25,374
8,000
22,600
38,999
212,214
2,102
5,011
6,989
2
BURY, Marina
BLANK, Volker
Université McGill
BLANK, Volker
BLANK, Volker
BLANK, Volker
Société canadienne du Cancer
Québec
Canada (IRSC)
Fondation des Maladies du Coeur
du Québec
Bayer Canada Inc.
Canada (IRSC)
Fondation des maladies du coeur
du Canada (FMCC)
Canada (IRSC)
National Institutes of Health (NIH)
(USA)
BLANK, Volker
BLOSTEIN, Mark
BLOSTEIN, Mark
BLOSTEIN, Mark
BLOSTEIN, Mark
RONCERO, Carlos
RONCERO, Carlos
Role of the transcription factor NFE 2L3 in cellular stress response and
tumorigenesis.
Novel regulatory pathways controlling hematopoietic stem cell fate.
Novel regulatory pathways controlling hematopoietic stem cell fate.
Contrôle de l'invasion de cellules de sein cancéreuses par des facteurs
de transcription de type CNC.
Regulation and function of NFE2L3: Linking transcription factor activity
to carcinogenesis.
Prospective cohort study on the safety of peri-operative management of
dabigatran.
Treatment of DVT, PE and SPAF.
Pharmacogenomic Study of Warfarin.
Role of gas6 and inflammation in the pathophysiology of venous
thromboembolism.
BLOSTEIN, Mark
Plane-wave quantitative ultrasound imaging of blood mechanical
properties
BLOSTEIN, Mark
U01HL087229 - Bridging anticoagulation in patients who Require
temporary Interruption of warfarin therapy for an elective invasive
proceDure or surGEry(BRIDGE) trial.
BLOSTEIN, Mark
Fondation des maladies du coeur Role of gas6 and inflammation in the pathophysiology of venous
du Canada (FMCC)
thromboembolism.
BORCHERS, Christoph
Université McGill
The Segal McGill Chair in Molecular Oncology at McGIll University and
the Jewish General Hospital.
BORCHERS, Christoph
Université McGill
BORCHERS, Christoph
Université McGill
BORCHERS, Christoph
Général Juif
BORCHERS, Christoph
Université McGill
BORCHERS, Christoph
Général Juif
BOUTROS, Marylise
Institut de Recherche du Centre
Natural history of diverticular abscess managed with non-operative
Universitaire de Santé de McGill
intent.
CHALIFOUR, Lorraine
Fondation des Maladies du Coeur Endocrine disruptor re-programming of the heart: mechanism and
du Québec
implications for the progression to disease.
CHEN-TOURNOUX, Annabel Instituts de recherche en santé du MITNEC B5: Non-isotope based imaging modalities vs 99mTc SPECT
Canada (IRSC)
myocardial perfusion imaging (MPI) to detect myocardial ischemia in
patients at high risk for ischemic cardiovascular events.
CHERTKOW, Howard
Société Alzheimer du Canada
Anomia in Alzheimer's disease: what causes an inability to name
objects and how could the situation be improved?
CHERTKOW, Howard
Anomia in Alzheimer's disease: what causes an inability to name
objects and how could the situation be improved?
CHERTKOW, Howard
Société Parkinson Canada
Comparing the nature and evolution of Mild Cognitive
Impairment in individuals with and without Parkinson's
disease
CHERTKOW, Howard
Instituts de recherche en santé du Comparing the nature and evolution of Mild Cognitive Impairment in
Canada (IRSC)
individuals with and without Parkinson's disease
CHERTKOW, Howard
Fonds de la recherche en santé du Consortium pour l'identification précoce de la Maladie d'Alzheimer Québec (FRSQ)
Québec (CIMA-Q).
CHERTKOW, Howard
Instituts de recherche en santé du Canadian Consortium on Neurodegeneration in Aging.
Canada (IRSC)
CHERTKOW, Howard
Instituts de recherche en santé du CCNA Agreement 1393: KT activities carried out by the CCNA
Canada (IRSC)
knowledge transfer cross-cutting program CCP. (Dalhousie University,
Halifax, Nova Scotia - Ken Rockwood)
CHERTKOW, Howard
Instituts de recherche en santé du H. Chertkow-Expession of interest for CCNA.
Canada (IRSC)
CHERTKOW, Howard
Instituts de recherche en santé du CCNA Agreement 1391: Issues in rural dementia care. (University of
Canada (IRSC)
Saskatchewan, Saskatoon, College of Nursing, Saskatoon,
Saskatchewan -Debra Morgan).
CHERTKOW, Howard
Alberta Prion Research InstituteCCNA Agreement 1388: Protein misfolding, sub-project 3D. (The
Alberta Ingenuity
Alberta Innovates - Bio Solutions (AI-Bio) - The Alberta Prion Research
Institute (APRI) - Andriy Kolavenko)
15,055
14,881
83,791
86,302
136,772
2,139
22,000
25,000
33,874
34,849
37,866
104,255
7,418
15,082
4,932
14,178
15,034
43,224
4,000
7,418
8,562
17,330
24,170
1,250
7,535
8,332
10,440
15,000
17,705
25,000
30,000
3
CHERTKOW, Howard
CHERTKOW, Howard
CHERTKOW, Howard
CHERTKOW, Howard
CHERTKOW, Howard
CHERTKOW, Howard
CHERTKOW, Howard
CHERTKOW, Howard
CHERTKOW, Howard
COHEN, Albert
Canada (IRSC)
Canada (IRSC)
Québec (FRSQ)
Canada (IRSC)
(USA)
Weston Brain Institute
Canada (IRSC)
Canada (IRSC)
QUEEN'S UNIVERSITY
PENNER, Jamie
COHEN, Albert
COHEN, S Robin
LAFOREST, Esther
COHEN, S Robin
BEAUCHEMIN, Antoine
COHEN, S Robin
Canada (IRSC)
COHEN, S Robin
COHEN, S Robin
Réseaux de centres d'excellence
du Canada (RCE)
Max Bell Foundation
Lu, Chang
EISENBERG, Mark
Université McGill
Touma, Lahoud
EISENBERG, Mark
Harel-Sterling, Lee
EISENBERG, Mark
Canada (IRSC)
Université McGill
GRANDI, Sonia
EISENBERG, Mark
Canada (IRSC)
EISENBERG, Mark
Canada (IRSC)
Canada (IRSC)
Canada (IRSC)
EISENBERG, Mark
EISENBERG, Mark
EISENBERG, Mark
EISENBERG, Mark
EISENBERG, Mark
EISENBERG, Mark
ERNST, Pierre-Paul
ERNST, Pierre-Paul
Vincent, Sophie
FILION, Kristian
Vincent, Sophie
FILION, Kristian
Canada (IRSC)
Université McGill
Canada (IRSC)
Canada (IRSC)
Canada (IRSC)
Canada (IRSC)
Canada (IRSC)
Canada (IRSC)
Université McGill
Canada (IRSC)
The impact of beta-amyloid burden on cognition in normal aging.
36,429
Entre le laboratoire et le chevet : validation de bio-marqueurs optimisés
par résonance magnétique pour le diagnostic clinique précoce et le
prognostic dans la maladie d'Alzheimer.
Alzeimer's disease cooperative study - project #1.
38,999
60,000
Clinical assessment of patients with AD and NEC individuals.
89,774
Development and validation of tau protein in saliva as an indicator for
early Alzheimer's Disease.
Anomia in Alzeimer's Disease: Untangling sematic components and
delivering therapy with rTMS.
Alzheimer's Research.
Canadian Consortium on Neurodegeneration in Aging - Full Proposal
Integrating a quality of life asessment and practice support system in
palliative homecare.
Inflammatory bowel disease.
Development and feasibility testing of a home-based physical activity
intervention for family caregivers of people with advanced cancer.
Exploring the implementation of a provisional program to train nurse
champions in a cardiac palliative approach.
Exploring how advanced cancer patients experience high or low
existential well-being: A mixed-methods study.
Integrating quality of life assessments into acute care for older adults
with chronic life-limiting illness.
Caring for the caregiver: Implementation of an evidence-based novel
service for family caregivers of cancer patients at the end of life
The safety and efficacy of ABSORB bioresorbable vascular scaffold: A
systematic review.
Apixaban and the risk of bleeding: a meta-analysis of randomized
controlled trials.
Pharmacological options for stroke prevention among patients
undergoing trans-aortic valve implantation (TAVI).
A population-based analysis of the trends in treatment and
management of patients with acute myocardial infarction complicated
by cardiogenic shock.
Hypertensive Disorders in Pregnancy and the Risk of Subsequent
Cardiovascular Disease
Optimizing physician training in motivational communication (MC) skills
for health behavior change
Optimizing physician training in motivational interviewing (MI) to
improve MI compentency, patient health behaviors, and morbidity
among patients with cardiovascular and chronic lung disease
Population Level Evaluation of Ablation Therapies in Atrial Fibrillation
The efficacy and safety of smoking cessation interventions in patients
with cardiovascular disease: A meta-analysis of randomized controlled
trials.
The clinical, regulatory, and ethical implications of electornic cigarettes:
A knowledge synthesis grant.
Evaluating the efficacy of E-cigarette use for smoking cessation (E3)
trial.
CIHR - Quebec Respiratory Health Training Program
The impact of a brief motivational intervention on adherence behavior in
asthmatics: A randomized controlled trial
Long-term outcomes for stenting versus endarterectomy for carotid
stenosis: A meta-analysis of randomized controlled trials.
Long-term outcomes for stenting versus endarterectomy for carotid
stenosis: A meta-analysis of randomized controlled trials.
49,984
112,720
153,303
286,562
2,526,092
4,242
36,440
4,167
11,831
19,992
5,436
31,495
1,000
2,834
3,125
35,000
35,000
4,339
4,540
17,211
49,980
91,484
161,604
8,125
11,783
2,000
2,834
4
FILION, Kristian
FILION, Kristian
FILION, Kristian
FILION, Kristian
WU, Mona
FOULKES, William David
WITKOWSKI, Leora
WITKOWSKI, Leora
WU, Mona
Di Iorio, Massimo
WITKOWSKI, Leora
Rivera Polo, Barbara
De Kock, Leanne
WU, Mona
ZAYED, Nadia
WITKOWSKI, Leora
Canada (IRSC)
Québec (FRSQ)
Québec (FRSQ)
Canada (IRSC)
Général Juif
Université McGill
The cardiovascular safety of varenicline: A population-based cohort
study.
Une évaluation populationelle des effets cardiovasculaires indésirables
des médicaments
Une évaluation populationelle des effets cardiovasculaires indésirables
des médicaments
A population-based assessment of the cardiovascular effects of 5-alpha
reductase inhibitors.
DICER1 mutations occurring in childhood anaplastic sarcoma of kidney.
New cases of small cell carcinoma of the ovary, hypercalcemic type
(SCCOHT).
AACR Annual Meeting 2014.
Towards creation of a dileri plezotropic tumour predisposition cell
model.
Université McGill
Deciphering the role of deep-intronic variants in mutation negative
DICER1-associated phenotypes.
Fonds de la recherche en santé du Facteurs Génétiques du Cancer de l'Ovaire Non-Épithéliale
Québec (FRSQ)
Université McGill
James McGill Professorship Award.
Ministère de l'Éducation, du Loisir 1)Characterization of rare variants in hereditary colorectal syndromes.
et du Sport (MELS) (Québec)
2) Dicer1, microRNA and childhood cancer.
Université McGill
Université McGill
DICER Research.
Fonds de la recherche en santé du In vitro modelling of DICER1-linked tumours
Québec (FRSQ)
Fundación Alfonso Martín
1)Characterization of rare variants in hereditary colorectal syndromes.
Escudero
Université McGill
Suscephbilité génétique au cancer du sein dans la population
canadienne québecoise.
Fonds de la recherche en santé du Recherche des mutations causales dans les tumeurs rares de l'ovaire.
Québec (FRSQ)
Fundación Alfonso Martín
1)Characterization of rare variants in hereditary colorectal syndromes.
Escudero
Génome Canada
Personalised risk stratification for prevention and early detection of
breast cancer.
Fonds de la recherche en santé du Simulation du coût/efficacité et du coût/utilité du dépistage des gènes
Québec (FRSQ)
de prédisposition au cancer du sein
Instituts de recherche en santé du A research and knowledge network on genetic health services and
Canada (IRSC)
policy: building on the APOGEE-Net and CanGeneTest experiences.
Génome Canada
breast cancer.
Génome Canada
breast cancer.
Génome Canada
breast cancer.
National Institutes of Health (NIH) PROSTATE CANCER SUSCEPTIBILITY: THE ICPCG STUDY
(USA)
Ministère des relations
Identification de nouveaux gènes de susceptibilité à la néoplasie
internationales du Québec
colorectale
Université McGill
Nomination for the Canadian Cancer Society's O. Harold Warwick Prize
in Cancer Control Research
Génome Canada
breast cancer.
Génome Canada
breast cancer.
Génome Canada
breast cancer.
Alliance canadienne pour la
Risk factor analysis of hereditary breast and ovarian cancer
recherche sur le cancer du sein
Ministère de l'enseignement
colorectale
supérieur, de la recherche, de la
science et de la technologie
(MESRST)
60,000
3,709
11,291
59,384
146
500
850
1,000
1,000
1,236
1,236
3,654
3,764
3,786
4,176
5,208
7,418
8,352
17,495
101
244
245
351
812
1,003
1,061
1,230
1,854
2,500
2,942
3,125
3,742
4,604
4,833
5
colorectale
5,501
Identification of new colorectal cancer susceptibility genes
Genome-wide approach to dissect driver pathways in small cell
carcinoma of the ovary, hypercalcaemic type
Axe banque de tissus et de données BTD / Réseau de recherche sur le
cancer / projet "Tumeurs sein / ovaire 26380
5,646
6,355
8,288
Fonds de la recherche en santé du Axe banque de tissus et de données BTD / Réseau de recherche sur le
Québec (FRSQ)
cancer / projet "Tumeurs sein / ovaire 26380
8,755
Québec
9,523
(MESRST)
Québec
Alpuche Lazcano, Sergio Paulo
FRIEDMAN, Ruby
GATIGNOL, Anne
BURUGU, Samantha
GATIGNOL, Anne
GATIGNOL, Anne
GATIGNOL, Anne
GATIGNOL, Anne
GATIGNOL, Anne
GATIGNOL, Anne
NGOMA, Alain
GREENAWAY, Christina
(MESRST)
Université McGill
Commission Européenne
Merck Sharp & Dohme Research
Laboratory
Québec
Pratiques de dépistage du cancer des non-porteuses de mutations
familiales des gènes BRCA1/2: Étendue, déterminants et impact
psychosocial du sur-dépistage
colorectale
La genetique du cancer du sein dans la population quebecoise : vingt
ansapres
BRCA1/2
Surgical Research.
Alex's Lemonade Stand Foundation DICER1 , microRNAs
and pediatric cancer: an emerging story
(USA)
Institut de recherche de la Société DICER1 and pituitary blastoma: Keys to understanding pituitary
development and tumorigenesis.
Institut de recherche de la Société Towards a biological understanding of small cell carcinoma of the
ovary, hypercalcemic type.
Institut de recherche de la Société DICER1 and pituitary blastoma: Keys to understanding pituitary
development and tumorigenesis.
Susan G. Komen Breast Cancer
hereditary Breat Cancer: Cause and Effect.
Foundation (The)
Alex's Lemonade Stand Foundation DICER1 , microRNAs
(USA)
and pediatric cancer: an emerging story
Pan-Canadian Colorectal Cancer Consortium (C4) - Phase 1
(IRTF)
Susan G. Komen Breast Cancer
hereditary Breat Cancer: Cause and Effect.
Foundation (The)
Geriatric Research.
Consejo Nacional de Ciencia y
Mechanisms of RNA interference and RNA Decay in cytoplasmic
Tecnologia (CONACYT) (Mexico) granules during HIV-1 replication in monocytes.
Fonds de la recherche en santé du Rôle de PKR et PACT dans l'activité de l'IFN de type I sur les
Québec (FRSQ)
lymphocytes T CD4+ infectés par le VIH.
Instituts de recherche en santé du Virus-cell interactions in the regulation of HIV translation.
Canada (IRSC)
Instituts de recherche en santé du Virus-cell interactions in the regulation of HIV translation.
Canada (IRSC)
Instituts de recherche en santé du The Canadian HIV Cure Enterprise (CanCURE)
Canada (IRSC)
Instituts de recherche en santé du Exploring interactions between HIV and the RNA interference pathway.
Canada (IRSC)
Instituts de recherche en santé du Development of antisense-based small RNA agents targeting the GAG
Canada (IRSC)
open reading frame of HIV-1 RNA for use in Gene and Drug therapy
against HIV-1 infection.
Université McGill
Estimating and comparing the burden of chronic hepatitis B infection in
the Immigrant and the Quebec born population: A population based
story.
Fonds de recherche du Québec - Centre Interuniversitaire québécois de statistiques sociales
Société et culture (FRQSC)
Instituts de recherche en santé du Accessibility and costs of healthcare for refugee claimants following
Canada (IRSC)
changes to the Interim Federal Health Program
Instituts de recherche en santé du Universal childhood Varicella vaccination program: Will it protect or
Canada (IRSC)
harm the immigrant population?
8,750
9,824
11,676
13,489
15,453
16,621
16,690
33,379
39,091
47,047
47,775
78,505
68,284
9,970
15,000
50,000
64,878
76,509
96,126
159,550
5,824
1,598
33,214
72,506
6
HILZENRAT, Nir
HILZENRAT, Nir
HIRSCH, Andrew
HOFFER, Leonard J.
HUDSON, Marie
HUDSON, Marie
HUDSON, Marie
NASRAH, Rima
HUDSON, Marie
HUDSON, Marie
JAGOE, Robert
JAGOE, Robert
Totten, Stephanie
Weisstock, Christina
JOHNSON, Nathalie
JOHNSON, Nathalie
JOHNSON, Nathalie
Sesques, Pierre
JOHNSON, Nathalie
Sesques, Pierre
JOHNSON, Nathalie
Totten, Stephanie
JOHNSON, Nathalie
JOHNSON, Nathalie
JOHNSON, Nathalie
JOHNSON, Nathalie
JOHNSON, Nathalie
JOHNSON, Nathalie
JOHNSON, Nathalie
KADER, Tina
Cohen, Jacqueline
KAHN, Susan Rebecca
KAHN, Susan Rebecca
KAHN, Susan Rebecca
KAHN, Susan Rebecca
KAHN, Susan Rebecca
KAHN, Susan Rebecca
KAHN, Susan Rebecca
KAHN, Susan Rebecca
corporations
corporations
Lotte & John Hecht Memorial
Foundation
Québec (FRSQ)
Québec (FRSQ)
Grifols Canada Ltd.
Société de l'arthrite (La)
Université McGill
IMPROVE - Individualized Management with Pegasys RBV Offering
Viral Eradication.
Improved care and education for patients with Hepatitis B.
196,160
Intersticial lung disease (ILD).
110,675
Open clinical trial to validate a short-term vitamin D loading and
maintenance dose protocol in people with advanced lung cancer.
Recherches observationnelles portant sur les maladies systemiques
autoimmunes rhumatismales
Recherches observationnelles portant sur les maladies systemiques
autoimmunes rhumatismales
The 1000 Canadian faces of lupus study.
Canadian inflammatory myopathy study group.
2013-14 TAS knowledge translation/networking.
New approaches to optimizing nutritional interventions in oncology
patients and cachexia.
Instituts de recherche en santé du Multimodal exercise, nutrition and anti-inflammatory treatment for
Canada (IRSC)
palliation of cancer cachexia: The MENAC study.
Université McGill
Role of Fas mutations in chemotherapy resistent lymphomas.
Université McGill
Overcoming therapeutic resistance in FAS-mutant lymphomas.
Fonds de la recherche en santé du Identification de biomarqueurs de prévision des lymphomes se
Québec (FRSQ)
présentant chez les adolescents et les jeunes adultes
Agence Rhône-alpes pour les
Elucidating the mechanism of therapeutic resistance in diffuse large B
Sciences Humaines et Sociales
cell lymphoma.
Roche Diagnostics
Elucidating the mechanism of therapeutic resistance in diffuse large B
cell lymphoma.
Instituts de recherche en santé du Role of Fas mutations in chemotherapy resistent lymphomas.
Canada (IRSC)
Québec (FRSQ)
Québec (FRSQ)
Fondation Cole
Help develop the cell library of the Quebec Leukemia Cell Bank with
young adult lymphoma cells.
Institut de recherche de la Société Optimizing therapy for STAT6-mutant DLBC.
Help develop the cell library of the Quebec Leukemia Cell Bank with
Général Juif
young adult lymphoma cells.
Instituts de recherche en santé du Overcoming therapeutic resistance in lymphoma.
Canada (IRSC)
Instituts de recherche en santé du The Metformin in women with type 2 diabetes in pregnancy trial ("MITY"
Canada (IRSC)
"The Study")
Université McGill
Antioxidant and lipid levels in relation to risk of preeclampsia and small
for gestational age in a large cohort of pregnant women from Montreal,
Canada.
Chaires de recherche du Canada Venous Thromboembolism
(CRC)
Instituts de recherche en santé du GENErVTE: Gene Gene Interactions and Recurrent Venous
Canada (IRSC)
Thromboembolism.
Fondation des maladies du coeur P. Wells - HSFO - Development and validation of clinical prediction ruls
de l'Ontario (Toronto, Ont)
for bleeding for patients on anticoagulant therapy for venous
thromboembolism.
Instituts de recherche en santé du A pilot study assessing feasibility of a randomized, placebo-controlled
Canada (IRSC)
trial of low-molecular-weight-heparin for postpartum prophylaxis in
women at risk of developing venous thromboembolism (pilot PROSPER
trial: PostpaRtum PrOphylaxiS for PE randomized
Instituts de recherche en santé du The SOX trial; Disseminating the unexpected results of a large, CIHR
Canada (IRSC)
North American RCT of elastic compression stockings to prevent the
post-thrombotic syndrome.
National Institutes of Health (NIH) Chronic venous thrombosis: Relief with adjunctive catheter-based
(USA)
therapy (C-TRACT) study.
Institut de Cardiologie de Montréal CIHR-ICRH CDP Application Preparation.
(ICM)
3,510
95,000
9,111
28,257
1,164
7,527
10,000
309
43,774
1,670
3,125
8,751
14,042
14,043
16,106
27,219
2,473
4,121
8,088
128,864
149,722
770
5,011
100,000
210
4,195
4,480
11,272
17,490
25,000
7
Jayasundera, Thiran
KAHN, Susan Rebecca
Canada (IRSC)
Extended venous thromboembolism prophylalis comparing rivaroxaban
to aspirin following total hip and knee arthroplasty (EPCAT II)
KAHN, Susan Rebecca
KAHN, Susan Rebecca
Sanofi-Aventis (Canada)
Canada (IRSC)
KAHN, Susan Rebecca
KAPUSTA, Michael
Pfizer Canada Inc.
Général Juif
Canada (IRSC)
Institut de recherche de la Société
Canada (IRSC)
Canada (IRSC)
Québec (FRSQ)
Université McGill
Canada (IRSC)
Université McGill
Thrombosis Fellowship.
Randomized controlled trail of anticoagulation vs. placebo for a first
symptomatic isolated distal deep-vein thrombosis (IDDVT): The
CACTUS-PTS Trial.
Venous Thromboembolism
TD FELLOWSHIP - Dr. Jayasundera.
KARAPLIS, Andrew C.
KAVAN, Petr
KAVAN, Petr
KLEIMAN, Lawrence C.
KLEIMAN, Lawrence C.
KLEIMAN, Simcha
CHOQUET, Karine
KLEINMAN, Claudia
DÉRY, Marc-André
LANGLEBEN, David
LEBLANC, Andréa
LEBLANC, Andréa
Lynham, Jeffrey
LEBLANC, Andréa
DÉRY, Marc-André
LEBLANC, Andréa
PAKAVATHKUMAR, Prateep
LEBLANC, Andréa
NOEL, Anastasia
LEBLANC, Andréa
LEBLANC, Andréa
LEBLANC, Andréa
LEBLANC, Andréa
LEBLANC, Andréa
LEBLANC, Andréa
LEBLANC, Andréa
LEBLANC, Andréa
SIMEONE, Stefania
LEBLANC, Andréa
LEHOUX, Stephanie
LEHOUX, Stephanie
LEHOUX, Stephanie
LEHOUX, Stephanie
BEITARI, Saina
LIANG, Chen
WANG, Yimeng
Liang, Zhibin
LIANG, Chen
LIANG, Chen
LIANG, Chen
LIANG, Chen
PTHrP and osteoblast biology: relevance to osteoporosis
Cognitive performance and psychosocial development in young adult
cancer survivors: A prospective, longitudinal study.
Young adult program.
Formation of the tRNALys packaging complex in HIV-1.
Regulation of primer tRNALys3 annealing to HIV-1 genomic RNA during
HIV-1 replication.
Jewish General Hospital Anesthesia Fellowship
Impact transcriptionnel d'une mutation dans le gène POLR3A chez un
modèle souris des leucodystrophies reliées à l'ARN polymérase III
Cath lab education fund.
Molecular mechanisms of neuronal cell death.
Role of the cytosolic prion protein in the regulation of Bax ubiquitination
and its impact on cell survival.
Finding effective inhibitors for Caspase-6 which is a new target in the
treatment of Alzeimer's disease.
Université McGill
Role of the cytosolic prion protein in the regulation of Bax ubiquitination
and its impact on cell survival.
Fonds de la recherche en santé du L'étude d'inhibiteurs de la Caspase-6 in vitro et in vivo pour développer
Québec (FRSQ)
une nouvelle stratégie thérapeutique pour la maladie Alzheimer
Traumatisme craniocérébral léger à répétition: impact sur la pathologie
tau et effets d'un agoniste LXR.
Université McGill
Université McGill
Fonds de la recherche en santé du Nouveaux modèles de la Maladie Alzheimer dans le poisson zébré.
Québec (FRSQ)
Instituts de recherche en santé du Regulation of prion protein expression, trafficking and function
Canada (IRSC)
Instituts de recherche en santé du Role of caspases in human neuronal cell death and in Alzheimer's
Canada (IRSC)
Disease.
Fonds de la recherche en santé du Consortium pour l'identification précoce de la Maladie d'Alzheimer Québec (FRSQ)
Québec (CIMA-Q).
Alzheimer's research funds.
Fonds de la recherche en santé du Mécanismes impliqués dans la réduction de la plaque d'athérosclérose
Québec (FRSQ)
par la contrainte de cisaillement.
Chaires de recherche du Canada Cardiovascular Physiology.
(CRC)
Instituts de recherche en santé du Potential roles of Semaphorin 3A in atherosclerosis.
Canada (IRSC)
Instituts de recherche en santé du Athero-protective shear stress signalling in the vasculature
Canada (IRSC)
Université McGill
Identifying the interaction between HIV-1 restriction factors and nuclear
pore complex.
Université McGill
Studying the anti-HIV activity of IFITM proteins.
China Scholarship Council (CSC) Identification of anti-HIV-1 interferon-stimulated genes and mechanistic
study of their antiviral activities.
Instituts de recherche en santé du Fusion and cell entry by oncogenic sheep retroviruses.
Canada (IRSC)
Canadian Foundation for AIDS
Investigate the anti-HIV-1 activity of interferon-induced MxB protein.
Research (CANFAR)
70,400
75,000
142,563
250,000
45,000
82,101
1,087
13,781
74,137
100,000
67,500
5,824
1,500
797
2,576
3,495
5,824
8,280
Université McGill
9,203
31,239
1,195
13,805
50,000
142,177
156,259
158,316
336,000
1,593
50,000
124,934
127,729
2,912
7,863
15,653
28,792
40,000
8
LIANG, Chen
LIANG, Chen
LIANG, Chen
LIANG, Chen
Liu, Yiliu
LIN, Rongtuan
SZE, Alexandre
LIN, Rongtuan
LIN, Rongtuan
LIN, Rongtuan
LIN, Rongtuan
LIN, Rongtuan
LIN, Rongtuan
LIN, Rongtuan
LIN, Rongtuan
LIPMAN, Mark L.
LONGTIN, Yves
LONGTIN, Yves
LONGTIN, Yves
LONGTIN, Yves
MAC NAMARA, Elizabeth
MAC NAMARA, Elizabeth
Negro Silva, Luis Fernando
Wu, Ting Hua (Joshua)
Bolt, Alicia Marie
Bolt, Alicia Marie
LEMAIRE, Maryse
MANN, Koren
MANN, Koren
MANN, Koren
MANN, Koren
MANN, Koren
MANN, Koren
MANN, Koren
MANN, Koren
MANN, Koren
MICHEL, Caroline
MICHEL, Caroline
DAHABIEH, Michael
PETRUCCELLI, Luca
MILLER, Wilson
MILLER, Wilson
MILLER, Wilson
Canada (IRSC)
Canada (IRSC)
Canada (IRSC)
Canada (IRSC)
Québec (FRSQ)
Research (CANFAR)
Cancer de la prostate Canada
Canada (IRSC)
Canada (IRSC)
Canada (IRSC)
Canada (IRSC)
Québec (FRSQ)
Studying the antiviral of bone marrow stromal cell antigen 2 and the
countering mechanism from HIV-1 Vpu.
Study the role of SAMHD1 in HIV-1 transmission.
75,000
Investigate the Antu-HIV-1 activity of interferon-induced MxB protein.
100,000
Study the antiviral fundtion of IFITM proteins.
123,708
Regulation of STING via the RIG-1 dependent RNA sensing pathway.
Caractérisation de l'apoptose induite par les ADNs produits lors
d'infections rétrovirales.
Ubiquitination promotes the survival of functional HIV-specific CD4+T
CM cells in elite controllers by decreasing Bim and Puma expression.
Combination oncolytic virotherapy for the treatment of prostate cancer.
Cross-talk between host antiviral and apoptotic signaling pathways in
de novo Dengue virus infection.
Combination oncolytic virotherapy for the treatment of prostate cancer.
Innate immunity and Hepatitis C virus infection.
Oncolytic virus therapy for HTLV-1 induced adult T cell leukemia.
Manipulating the RIG-1 signaling pathway to inhibit influenza virus
infection.
Hemodialysis Research.
- Les infections nosocomiales - Une approche globale et intégrative
pour mieux comprendre et prévenir la diarrhée associée au C. difficile
et améliorer l'hygiène des mains
Fonds de la recherche en santé du - Les infections nosocomiales - Une approche globale et intégrative
Québec (FRSQ)
Québec (FRSQ)
Québec (FRSQ)
Génome Québec
Clinical implementation and outcomes evaluation of blood-based
biomarkers for COPD management.
Génome Canada
Clinical implementation and outcomes evaluation of blood-based
biomarkers for COPD management.
Université McGill
Contribution of arsenic to enhance atherosclerosis.
Université McGill
Tungsten-induces alteration B lymphocytes.
Fondation Cole
The role of Tungsten in preB Cell Leukemogenesis.
Fondation Cole
The role of Tungsten in preB Cell Leukemogenesis.
Instituts de recherche en santé du Mechanisms of arsenic-induced atherosclerosis.
Canada (IRSC)
Institut de recherche de la Société Optimizing therapy for STAT6-mutant DLBC.
Leukemia & Lymphoma Society of The role of mutated Ras-associating proteins in R-CHOP-resistant
Canada (The) (LLSC)
DLBCL.
Canada (IRSC)
Canada (IRSC)
(USA)
Centre universitaire de santé McGill
(CUSM)
Université McGill
Université McGill
Canada (IRSC)
72,135
Bone as a target for Tungsten-induced toxicities.
Mechanisms of arsenic-enhanced atherosclerosis.
Phosphodiesterase Type 5 inhibition with Tadalafill changes outcomes
in heart failure (PITCH-HF).
The ACE switchback study.
Mechanisms of drug resistance in melanoma and lymphoma cells.
McGill James
Improving combination therapies involving histone deacetylare inhibitors
and DNA methyltransferare inhibitors in hematological malignancies
582
18,407
14,835
24,725
56,250
75,275
87,153
142,154
167,623
143,733
8,334
26,065
2,473
7,527
216,680
326,897
6,989
7,863
9,890
30,110
31,250
8,088
45,165
50,000
154,580
2,940
7,250
635
797
883
9
ZHAN, Yao
MILLER, Wilson
Kaddour, Nancy
DAHABIEH, Michael
ZHAN, Yao
MILLER, Wilson
MILLER, Wilson
MILLER, Wilson
Guo, Qianyu
MILLER, Wilson
DUPÉRÉ-RICHER, Daphné
Guo, Qianyu
MILLER, Wilson
MILLER, Wilson
Kaddour, Nancy
Guo, Qianyu
MILLER, Wilson
MILLER, Wilson
FRIEDMANN, Jennifer Elisabeth
MILLER, Wilson
MILLER, Wilson
DUPÉRÉ-RICHER, Daphné
DAHABIEH, Michael
MILLER, Wilson
MILLER, Wilson
MILLER, Wilson
MILLER, Wilson
MILLER, Wilson
MILLER, Wilson
MILLER, Wilson
MILLER, Wilson
MILLER, Wilson
MILLER, Wilson
MILLER, Wilson
MILLER, Wilson
MILLER, Wilson
MONETTE, Johanne
MONETTE, Johanne
WRIGHT, Kathryn
MORAIS, José Antonio
WRIGHT, Kathryn
Seltzer, Sean
Rao, Shringar
Rao, Shringar
Alpuche Lazcano, Sergio Paulo
MOULAND, Andrew
MOULAND, Andrew
MOULAND, Andrew
MOULAND, Andrew
MOULAND, Andrew
MOULAND, Andrew
MOULAND, Andrew
Université McGill
Role of eIF4E in promoting melanoma cell proliferation and maintaining
acquired resistance to Vemurafenib in melanoma.
Université McGill
Effect of EiF4E knockdown on EMT.
Université McGill
Mechanisms of drug resistance in melanoma and lymphoma cells.
Role of eIF4E in promoting melanoma cell proliferation and maintaining
acquired resistance to Vemurafenib in melanoma.
Université McGill
Elucidate the mechanism of the increased anti-leukemic potency of
darinaparsin compared to arsenic trioxide.
Fondation Cole
Anti-cancer activity of HDAC inhibitors.
Université McGill
Université McGill
Effect of EiF4E knockdown on EMT.
Fondation Cole
Université McGill
McGill James
Université McGill
Sophisticated new approaches in immuno-therapy and novel targeted
therapy in melanoma.
Fondation Cole
Anti-cancer activity of HDAC inhibitors.
Fonds de la recherche en santé du mécanismes de résistance aux médicaments dans les hémopathies
Québec (FRSQ)
malignes
Samuel Waxman Cancer Research Development of novel anti-cancer therapies using arsenic trioxide.
Foundation
Université McGill
McGill James
Université McGill
Bridge Funding.
Functional role of elF4E in breast tumor metastasis and epithelial-tomesenchymal transition (EMT).
Instituts de recherche en santé du Molecular mechanisms of retinoids as anti-virals in respiratory virus
Canada (IRSC)
infections
Samuel Waxman Cancer Research Development of novel anti-cancer therapies using arsenic trioxide.
Foundation
Instituts de recherche en santé du Targeting the eukaryotic translation factor elF4E with ribavirin in breast
Canada (IRSC)
cancer.
Université McGill
Rossy Cancer Network (RCN).
Instituts de recherche en santé du Mechanisms of response and resistance in epigenetic therapy in
Canada (IRSC)
hematological malignancy.
8th International Conference of differentiation therapy - Montreal
October 3-6,1999.
Instituts de recherche en santé du The CIHR/FRSQ Training Program in Cancer Research at McGill
Canada (IRSC)
Instituts de recherche en santé du RADAR : A new screening tool to improve the recognition of delirium
Canada (IRSC)
among elder persons
Fonds de la recherche en santé du Utilisation des services médicaux d'urgence et hospitaliers chez la
Québec (FRSQ)
clientèle âgée de 75 ans et plus : Quel est l'impact de l'accès aux
ressources médicales et communautaires de première ligne ?
Fonds de la recherche en santé du L'impact de l'exercice et de la supplémentation en leucine sur le muscle
Québec (FRSQ)
squelettique de femmes âgées fragillisées avec une exploration des
mécanismes justificatifs
Fonds de la recherche en santé du L'impact de l'exercice et de la supplémentation en leucine sur le muscle
Québec (FRSQ)
squelettique de femmes âgées fragillisées avec une exploration des
mécanismes justificatifs
Instituts de recherche en santé du Veillissement et les maladies chroniques de RUIS McGill (Réseau
Canada (IRSC)
Montreal General Hospital
Helen McCall Hutchison award in geriatric medicine
Foundation (Can)
Université McGill
Why HIV-1 dismantles NPCs?
Université McGill
Studies on HIV-1 cure.
Université McGill
Studies on HIV-1 cure.
Mechanisms of RNA interference and RNA Decay in cytoplasmic
Tecnologia (CONACYT) (Mexico) granules during HIV-1 replication in monocytes.
Instituts de recherche en santé du The Canadian HIV Cure Enterprise (CanCURE)
Canada (IRSC)
Instituts de recherche en santé du Understanding how the HIV-1-dependent ribonucleoprotein counters
Canada (IRSC)
host stress responses
Instituts de recherche en santé du Evading and subverting host cell machineries to ensure HIV-1 genomic
Canada (IRSC)
RNA fate.
1,000
1,241
1,978
2,000
2,967
5,440
5,724
6,989
8,657
9,203
15,055
16,560
16,703
10,903
15,000
20,000
24,378
34,525
40,498
70,880
96,099
145,977
162,000
162,500
1,500
1,598
835
1,165
284
495
1,269
4,368
6,698
9,970
63,627
134,164
158,294
10
Borrelli, Daniel
Sharif-Askari, Bahram
PANASCI, Lawrence
PANASCI, Lawrence
PANASCI, Lawrence
PANASCI, Lawrence
PANASCI, Lawrence
PANTOPOULOS, Kostas
PANTOPOULOS, Kostas
PANTOPOULOS, Kostas
PANTOPOULOS, Kostas
CHO, Chulmin
PAUDEL, Hemant
CHO, Chulmin
PAUDEL, Hemant
Jinhai, Duan
PAUDEL, Hemant
PAUDEL, Hemant
PAUDEL, Hemant
Yancu, Debbie
Laaribi, Haithem
Ruiz-Rosado, Azucena
POLLAK, Michael
POLLAK, Michael
POLLAK, Michael
POLLAK, Michael
POLLAK, Michael
POLLAK, Michael
POLLAK, Michael
POLLAK, Michael
POLLAK, Michael
POLLAK, Michael
POLLAK, Michael
POLLAK, Michael
POLLAK, Michael
Zidova, Zuzana
PONKA, Prem
PONKA, Prem
PONKA, Prem
Jacob, Arthur
RICHARD, Stéphane
DARBELLI, Lama
SONG, Jingwen
RICHARD, Stéphane
RICHARD, Stéphane
RICHARD, Stéphane
LI, Naomi
RICHARD, Stéphane
Université McGill
Université McGill
Conseil de Recherches en
Sciences Naturelles et Génie du
Canada (CRSNG)
Canada (IRSC)
Institut de recherche de la Société
Université McGill
Canada (CRSNG)
Canada (IRSC)
BKM120 in combination with chemotherapeutic drugs in CLL therapy.
New formation of drugs encapsulated into DNA cage delivery system.
Donations.
DNA cages as a platform for efficient and selective delivery of
therapeutics into tumour cells.
DNA cages as a platform for efficient and selective delivery of
therapeutics into tumour cells.
Targeting cancer by small molecule inhibitors of iron regulatory protein
2 (IRP2).
Iron and metabolism research.
Iron metabolism and hepatitis C virus.
Iron regulatory proteins: pathophysiological functions in metabolism and
cancer.
Developmentally regulated brain protein in Alzheimer's disease: Its role
in synaptic dysfunction.
Developmentally regulated brain protein in Alzheimer's disease: Its role
in synaptic dysfunction.
Guangdong Province Science and Examine the development of Alzheimer neuropathology in mouse
Technology Foundation
model.
Restoration of synapse loss in AD by replenishment of drebrin in the
CNS.
Instituts de recherche en santé du Neurofibrillary pathology and amyloidogenesis in Alzheimer's disease:
Canada (IRSC)
mechanistic insights.
Université McGill
A study on metformin and its implications in cancer treatment.
Université McGill
Effect of LDH-A inhibition with metformin treatment in cancer.
Dose dependent effect of metformin in 4T1 mammary carcinoma growth
Tecnologia (CONACYT) (Mexico) and phosphoprotein expression.
Development of an instrument for assessing occupational exposures in
canacer Inc
cancer case-control studies and its implication to cancers of lung, brain,
ovary and colon.
Development of an instrument for assessing occupational exposures in
canacer Inc
cancer case-control studies and its implication to cancers of lung, brain,
ovary and colon.
Institut de recherche de la Société Defining the roles of systemic and direct tumour effects of biguanides to
optimize treatment.
Instituts de recherche en santé du Defining and Applying "Oncometabolism": A team approach in
Canada (IRSC)
understanding and translating the Warburg effect from oncogenic and
tumour suppressing activities.
National Institutes of Health (NIH) An investigation of circulating adiponectin levels and monoclonal
(USA)
gammopathy of undetermined significance (MGUS).
Unraveling metabolic adaptations associated with disease progression
(IRTF)
and therapeutic reponse in metastatic breast cancer
IGF and breast cancer.
Stroll - cancer screening.
National Institutes of Health (NIH) A pooled investigation of circulating adiponectin levels and risk of
(USA)
multiple myeloma.
National Institutes of Health (NIH) Nurses' health study I and II women's lifestyle validation study.
(USA)
European Union (EU) Research
Investigation of the Role of Heme-Oxigenase I in the Erythroid
Directorate General
Differentation
Instituts de recherche en santé du Chelation, mobilization and metabolism of storage iron.
Canada (IRSC)
Instituts de recherche en santé du Regulation of iron metabolism and heme synthesis in erythroid cells.
Canada (IRSC)
Université McGill
The role of monomethylarginene and symmetric dimethylarginine
gererated by PRMT5 and PRMT7 during the DNA damage signalling.
Université McGill
To identify alternatively spliced RNA targets of QKI in glial cells.
Université McGill
Université McGill
Does the Sam68 STAR RNA binding protein reuglate mTOR alternative
splicing and mTOR signaling pathway? What are the roles of Sam68 in
neu-oncogene-breast cancer development.
Université McGill
To define the role of Sam68 in p53-mediated functions.
2,000
4,945
28,000
33,334
66,667
16,209
17,500
36,000
148,200
5,200
15,830
24,740
18,544
130,276
956
3,225
6,384
5,087
7,737
10,014
16,773
23,566
25,405
35,545
39,711
69,801
161,040
33,045
117,763
133,831
652
1,058
1,648
1,893
2,115
11
Blanc, Roméo
NEAULT, Mathieu
RICHARD, Stéphane
RICHARD, Stéphane
LI, Naomi
Blanc, Roméo
BUENO, Murilo
RICHARD, Stéphane
RICHARD, Stéphane
RICHARD, Stéphane
NEAULT, Mathieu
RICHARD, Stéphane
RICHARD, Stéphane
De Bruin, Ruben
RICHARD, Stéphane
RICHARD, Stéphane
RICHARD, Stéphane
RICHARD, Stéphane
RICHARD, Stéphane
RICHARD, Stéphane
RICHARD, Stéphane
RICHARD, Stéphane
RICHARD, Stéphane
RICHARDS, Brent
RICHARDS, Brent
RICHARDS, Brent
MANOUSAKI, Despoina
RICHARDS, Brent
RICHARDS, Brent
RICHARDS, Brent
RICHARDS, Brent
RICHARDS, Brent
RICHARDS, Brent
Blank, Nimrod
RUDSKI, Lawrence
Blank, Nimrod
RUDSKI, Lawrence
Ouerd, Sofiane
SCHIFFRIN, Ernesto
MIAN, Muhammad Oneeb Rehman SCHIFFRIN, Ernesto
IDRIS KHODJA, Noureddine
SCHIFFRIN, Ernesto
Trindade, Michelle
SCHIFFRIN, Ernesto
Al Nashmi, Tofol
SCHIFFRIN, Ernesto
Ouerd, Sofiane
SCHIFFRIN, Ernesto
Université McGill
Québec (FRSQ)
Université McGill
Université McGill
Québec (FRSQ)
Université McGill
Québec (FRSQ)
UNIVERSITAIR MEDISCH
CENTRUM (UTRECHT)
Université McGill
Université McGill
The role of PRMTs in stem cell differentiation.
Étude de la régulation de la signalisation du dommage à l'ADN par la
méthylation d'arginine et les microARNs dans les cellules cancéreuses.
To define the role of Sam68 in p53-mediated functions.
The role of PRMTs in stem cell differentiation.
L'évaluation du rôle de la Jumonji demethylase KDM2A au cours de la
réponse aux dommages de l'ADN
Étude de la régulation de la signalisation du dommage à l'ADN par la
méthylation d'arginine et les microARNs dans les cellules cancéreuses.
The role of he RNA-binding protein quaking in inflammation.
Defining the regulation of platelet-derived growth factor (PDGF)
signaling by protein arginine methylation.
Defining the regulation of platelet-derived growth factor (PDGF)
signaling by protein arginine methylation.
Société Canadienne de la sclérose The role of quaking proteins in oligodendrocyte physiology and
en plaques
myelation.
Instituts de recherche en santé du The role of the Sam68 RNA binding protein in normal and diseased
Canada (IRSC)
cells.
Instituts de recherche en santé du The role of post-translational modifications of MRE11 in mediating the
Canada (IRSC)
DNA damage response.
Instituts de recherche en santé du Defining the role of protein arginine methyltransferases (PRMTs) and
Canada (IRSC)
RGG/RG motifs in cancer in the maintenance of genomic stability.
Fonds de la recherche en santé du Des causes à la clinique : Comprendre les déterminants génétiques de
Québec (FRSQ)
la maladie commune et, ainsi, permettre l'amélioration des soins aux
patients
2014 Dr. Jody Ginsberg Young Investigator Award
Société canadienne
d'endocrinologie et métabolisme
(SCEM)
Fonds de la recherche en santé du Des causes à la clinique : Comprendre les déterminants génétiques de
Québec (FRSQ)
la maladie commune et, ainsi, permettre l'amélioration des soins aux
patients
Groupe canadien d'endocrinologie The role of rare and low-frequency genetic variation in vitamin D status.
pédiatrique (GCEP)
Université McGill
Genetic determinants of 25-Hydroxy Vitmain D Levels
Instituts de recherche en santé du Full resolution metabolic disease epigenomics in human populations
Canada (IRSC)
Université McGill
Type 2 diabetes, glucose and coronary heart disease, a Mendelian
randomization study.
Instituts de recherche en santé du Full resolution metabolic disease epigenomics in human populations
Canada (IRSC)
Instituts de recherche en santé du Pinpointing causal variants for osteoporosis.
Canada (IRSC)
Israel Cancer Research Fund
ICRF Fellowship.
(ICFR)
Israel Cancer Research Fund
ICRF Fellowship.
(ICFR)
Université McGill
Role of vascular smooth muscle cell PPAR-gamma in endothelin-1induced vascular disease.
Réseaux de centres d'excellence
Role of T regulatory lymphocytes in adlosterone-induced hypertension
du Canada (RCE)
Société Québécoise d’hypertension Oxidative stress mechanisms in vasculature of atherosclerotic type 1
artérielle
diabetic mice.
Foundation for the Coordination of Hypertension in Vascular Biology
Higher Education and Graduate
Training (CAPES Foundation)
(Brazil)
Saudi Arabian Cultural Bureau in
Gene expression profile in small resistance arteries in patients with
Canada
hypertension with and without nephroangiolsclerosis and its relation to
small and large artery function remodeling.
Instituts de recherche en santé du Role of vascular smooth muscle cell PPAR-gamma in endothelin-1Canada (IRSC)
induced vascular disease.
2,724
4,945
6,989
6,989
7,500
8,352
15,055
365,118
2,473
12,527
25,055
34,945
95,000
111,600
174,669
193,592
8,334
20,000
26,065
60,000
1,500
8,330
14,128
41,633
172,964
12,363
37,637
1,692
2,904
6,181
10,322
10,484
13,173
12
BARHOUMI, Tlili
BARHOUMI, Tlili
IDRIS KHODJA, Noureddine
SCHIFFRIN, Ernesto
SCHIFFRIN, Ernesto
SCHIFFRIN, Ernesto
SCHIFFRIN, Ernesto
COELHO, Suellen Cristina
SCHIFFRIN, Ernesto
Fraulob Aquino, Julio Cesar
SCHIFFRIN, Ernesto
SCHIFFRIN, Ernesto
SCHIFFRIN, Ernesto
SCHIFFRIN, Ernesto
SCHIFFRIN, Ernesto
SCHIFFRIN, Ernesto
SCHIFFRIN, Ernesto
SCHIFFRIN, Ernesto
SCHIFFRIN, Ernesto
SCHIPPER, Hyman Morris
SMALL, David
SMALL, David
SMALL, David
Khosrow-Khavar, Farzin
SUISSA, Samy
SUISSA, Samy
SUISSA, Samy
Khosrow-Khavar, Farzin
SUISSA, Samy
Tascilar, Koray
SUISSA, Samy
SUISSA, Samy
SUISSA, Samy
WU, Jennifer
SUISSA, Samy
Faillie, Jean-Luc
SUISSA, Samy
SUISSA, Samy
SUISSA, Samy
SUISSA, Samy
SUISSA, Samy
SUISSA, Samy
SUISSA, Samy
SUISSA, Samy
SUISSA, Samy
SUISSA, Samy
Université McGill
Université McGill
Québec (FRSQ)
Chaires de recherche du Canada
(CRC)
Conselho Nacional de
Desenvolvimento Científico e
Tecnológico (CNPq) (Brazil)
Conselho Nacional de
Desenvolvimento Científico e
Tecnológico (CNPq) (Brazil)
(CRC)
(CRC)
Juvenile Diabetes Research
Foundation International
Canada (IRSC)
Canada (IRSC)
Canada (IRSC)
(USA)
Canada (IRSC)
corporations
Université McGill
Université McGill
Québec (FRSQ)
Général Juif
Université McGill
Université McGill
Gouvernement de la Turquie
Canada (IRSC)
Université McGill
Université McGill
Société francophone du diabète
(SFD)
Canada (IRSC)
Canada (IRSC)
Université McGill
Université McGill
Canada (IRSC)
Canada (IRSC)
Canada (IRSC)
Pathophysiology of hypertension.
Pathophysiology of hypertension.
L'endothéline-1, les isoformes de NOX et le stress oxydant dans
l'athérosclérose associée au diabète de type 1
Hypertension and vascular research.
15,659
21,841
22,582
Endothelin, vascular inflammation and injury, and hypertension.
25,051
Vascular remodeling in hypertension.
38,108
75,171
100,137
24,658
Rodent phenotyping facility.
Nox-derived Rox: Renal and vascular complications of type 1 diabetes.
781
14,754
Cardiohhypertension research "Fonds d'urgence".
MicroRNAs and gene regulation on vascular remodeling in hypertension
from mice to humans.
T-regulatory cells and vascular injury in hypertension
40,000
123,293
142,230
Endothelin, vascular inflammation and injury, and hypertension.
149,170
Clinical assessment of patients with AD and NEC individuals.
89,774
Mary Katz Claman Foundation Funds.
146,018
Role of HO-1 in aging & Parkinsonian neural tissues III.
150,784
Pulmonory Oncology Staff.
Airway center.
Pulmonary Research.
3,000
15,000
26,400
James McGill Professor.
James McGIll Professor.
The use of stains and prevention of colorectal cancer-specific mortality.
797
797
1,566
The use of stains and prevention of colorectal cancer-specific mortality.
5,000
Cardiovascular risk prediction for primary prevention in patients with
rheumatoid arthritis.
The use of insulin glargine and risk of colorectal cancer in patients with
type 2 diabetes.
Pharmacoépidémiologie et pharmacologie sociale des médicaments du
diabète de type 2.
CIHR - Quebec Respiratory Health Training Program
9,203
9,203
15,000
Prince Edward Island Canadian Network for observational drug effect
studies (CNODES) demonstration project.
Propensity scores and marginal structural models in drug safety
research
Newfoundland and Labrador CNODES demonstration project.
Canadian Network for Observational Drug Effect Studies.
35,000
1,195
1,195
2,805
8,125
8,505
13,805
13,805
28,150
116,465
3,180,100
13
TAGALAKIS, Vicky
Canada (IRSC)
TAGALAKIS, Vicky
Fondation des Maladies du Coeur
du Québec
TAGALAKIS, Vicky
Canada (IRSC)
THERRIEN, Judith
Canada (IRSC)
Canada (IRSC)
Canada (IRSC)
Université McGill
Rare Disease Foundation (The)
JEWETT, Lisa
THOMBS, Brett
KWAKKENBOS, Linda
THOMBS, Brett
JEWETT, Lisa
THOMBS, Brett
THOMBS, Brett
LEVIS, Alexander
THOMBS, Brett
Canada (IRSC)
JEWETT, Lisa
THOMBS, Brett
DELISLE, Vanessa
THOMBS, Brett
JEWETT, Lisa
THOMBS, Brett
MILETTE, Katherine
THOMBS, Brett
Rheumatology Research
Foundation
Rheumatology Research
Foundation
Canada (CRSNG)
Canada (IRSC)
RAZYKOV, Ilya
THOMBS, Brett
THOMBS, Brett
KWAKKENBOS, Linda
THOMBS, Brett
THOMBS, Brett
JEWETT, Lisa
THOMBS, Brett
THOMBS, Brett
New oral anticoagulants for the prevention of venous thromboembolism
in high-risk ambulatory cancer patients: A randomized placebocontrolled, double-blind clinical trial.
Screening for occult malignancy in patients with unprovoked venous
thromboembolism: a randomized controlled trial using a comprehensive
computed tomography of the abdomen/pelvis (SOME trial).
1,200
The use of extended peri-operative low molecular weight heparin to
improve cancer specific survival following surgical resection of colon
cancer: A randomized controlled trial - PERIOP-01.
The Canadian outcomes registry late after TEtralogy of fallot repair
(CORRELATE).
Une intervention visant à réduire la détresse reliée à l'image corporelle
chez les femmes avec défigurement causé par la sclérodermie
Scleroderma patient-centered interventions network (SPIN).
12,884
5,500
Social anxiety from disfigurement due to medical illness: From
assessment to intervention.
5,987
THOMBS, Brett
THOMBS, Brett
MCGEE, Shauna
Mokhtar, Shaza
TRIFIRO, Mark A
TRIFIRO, Mark A
MCGEE, Shauna
TRIFIRO, Mark A
TRIFIRO, Mark A
254
Health Professional Research Preceptorship.
TRIFIRO, Mark A
THOMBS, Brett
36
5,500
TRIFIRO, Mark A
THOMBS, Brett
THOMBS, Brett
1,000
William Dawson Scholar
Testing the feasibility of the changing faces practitioner training and
induction program for scleroderma patients.
Assessing excess significance bias in randomized controlled trials of
non-pharmacological interventions for pain management in rheumatic
diseases.
Health Professional Research Preceptorship.
Barriers to depression screening in medical setting: Examining
cumulative false-positive rates and possible solutions in rheumatology,
oncology, and cardiovascular care settings.
Université McGill
Instituts de recherche en santé du Understanding suicidal thinking and risk in a chronic, progressive
Canada (IRSC)
disease: From epidemiology to application.
The Scleroderma patient-centred intervention Network (SPIN).
Fonds de la recherche en santé du La fatigue lié aux maladies chroniques dans la sclérodermie: de
Québec (FRSQ)
l'évaluation à l'intervention
The Scleroderma patient-centred intervention Network (SPIN).
Instituts de recherche en santé du Social anxiety from disfigurement due to medical illness: From
Canada (IRSC)
assessment to intervention.
Université McGill
Searching for identity in the dark: The experiences of women living in
rare and unpredictable disease.
Sciences Humaines du Canada
(CRSH)
Université McGill
International Consortium for Bevavorial/Educational/Psychological
Interventions for Scleroderma. - SPIN COHORT NETWORK.
Instituts de recherche en santé du The Scleroderma patient-centered intervention network (SPIN)
Canada (IRSC)
feasibility trial planning meeting.
Research Foundation Sir Mortimer International Consortium for Bevavorial/Educational/Psychological
B. Davis, Jewish General Hospital Interventions for Scleroderma. - SPIN COHORT NETWORK.
Instituts de recherche en santé du Emerging Team: The Scleroderma patient-centered intervention
Canada (IRSC)
Network.
Université McGill
Dissecting and modeling networks for cancer cell survival.
Saudi Arabian Cultural Bureau in
Understanding the molecular pathology of spinal and bulbar muscular
Canada
atrophy by identifying genetic interactors of an AR-Humanized fly.
Instituts de recherche en santé du Approche de la biologie des systèmes à l'hétérogénéité tumorale dans
Canada (IRSC)
le cancer de la prostate
Novel targeting abiotic therapeutics and imaging agents for prostate
cancer.
Androgen receptor-mediated translational regulation in prostate cancer.
THOMBS, Brett
THOMBS, Brett
4,945
Novel targeting abiotic therapeutics and imaging agents for prostate
cancer.
1,195
3,221
5,000
12,355
13,805
14,615
21,635
30,000
65,865
70,000
797
6,234
9,203
14,325
14,629
50,000
299,958
1,692
8,736
17,500
14,830
21,548
44,995
14
KHANASSOV, Vladimir
TRIFIRO, Mark A
TRIFIRO, Mark A
TRIFIRO, Mark A
Artificial pancreas research project.
Insulin pump center.
Androgen receptor-mediated translational regulation in prostate cancer.
50,000
75,791
79,139
TRIFIRO, Mark A
Canada (IRSC)
Québec (FRSQ)
Innovative approaches to functional characterization of the androgen
receptor in prostate cancer.
Endocrinology research and development.
Gestion de cas pour les patients avec des troubles cognitifs en soins de
santé primaires et communautaires: obstacles à l'implantation. Revues
systématiques mixtes de la littérature
Maladie d'Alzheimer et multimorbidité : adapter et améliorer la qualité et
l'efficacité des services de première ligne
Maladie d'Alzheimer: adapter et améliorer la qualité et l'efficacité des
services de première ligne
Veillissement et les maladies chroniques de RUIS McGill (Réseau
Déterminants de la continuité des soins aux personnes âgées
vulnérables inscrites auprès d'un médecin d'une unité de médecine
familiale du Québec : une étude transversale.
Start-Up Funds - Epidemiology
102,692
TRIFIRO, Mark A
VEDEL, Isabelle
VEDEL, Isabelle
VEDEL, Isabelle
VEDEL, Isabelle
VEDEL, Isabelle
VEDEL, Isabelle
VEDEL, Isabelle
VEDEL, Isabelle
VEDEL, Isabelle
VEDEL, Isabelle
VEDEL, Isabelle
Liang, Jia Ming (Calvin)
King, Stacey
Cutillas, Vincent
WAINBERG, Mark A.
WAINBERG, Mark A.
WAINBERG, Mark A.
WAINBERG, Mark A.
King, Stacey
QUASHIE, Peter
WAINBERG, Mark A.
WAINBERG, Mark A.
ANSTETT, Kaitlin
SINGHROY, Diane
Zanichelli, Veronica
ANSTETT, Kaitlin
WAINBERG, Mark A.
WAINBERG, Mark A.
WAINBERG, Mark A.
WAINBERG, Mark A.
DEPATUREAUX, Agnes
WAINBERG, Mark A.
HASSOUNAH, Said
WAINBERG, Mark A.
WAINBERG, Mark A.
WAINBERG, Mark A.
WAINBERG, Mark A.
WAINBERG, Mark A.
WAINBERG, Mark A.
WAINBERG, Mark A.
WAINBERG, Mark A.
WAINBERG, Mark A.
WAINBERG, Mark A.
Québec (FRSQ)
Canada (IRSC)
Canada (IRSC)
Québec (FRSQ)
Québec (FRSQ)
Québec (FRSQ)
Canada (IRSC)
Fonds de recherche du Québec - Plan d'action ministériel sur les troubles cognitifs liés au vieillissement:
Santé (FRQS)
une évaluation de l'implantation et des résultats des projets initiaux en
vue d'une généralisation progressive au Québec.
Research Foundation Sir Mortimer Start-Up Funds - Epidemiology
Université McGill
Effect of integrasi inhibitor, dolutegraivre, on the molecular evolution.
University of Liverpool (The) (UK) Selection of HIV drug resistance against novel compounds.
Université McGill
Instituts de recherche en santé du The addition of R262K to the H51Y mutation in HIV-1 subtype B
Canada (IRSC)
integrase confers low-level resistance against dolulegravir.
University of Liverpool (The) (UK) Selection of HIV drug resistance against novel compounds.
Instituts de recherche en santé du Drug resistance of HIV to second generation integrase inhibitors.
Canada (IRSC)
Université McGill
Investigating resistance phenotypes in HIV-1.
Université McGill
The contribution of cellular PRMT6 to HIV-1 pathogenesis.
University of Padova
Studies on HIV drug resistance involving integrase inhibitors.
Instituts de recherche en santé du Investigating resistance phenotypes in HIV-1.
Canada (IRSC)
Réseau Canadien pour les Essais HIV-1 group O integrase: Impact of genetic polymorphisms on integrase
VIH (Vancouver, B.C.)
inhibitors resistance (IIs) and on enzymatic activity.
Université McGill
Fonds de la recherche en santé du Validation de SIVmac239 comme un modèle primate non humain pour
Québec (FRSQ)
l'étude de la résistance du VIH aux inhibiteurs d'intégrase
Université McGill
Université McGill
National Institutes of Health (NIH) HIV Prevention Trial Network Leadership: Biomedical Sciences
(USA)
Committee Chair
Investigating the role of subtype-specific polymorphisms in HIV-1
Research (CANFAR)
resistance to integrase inhibitors.
Québec Conference.
Fonds de la recherche en santé du SIDAMI-Surveillance de l'épidémie de résistance du VIH.
Québec (FRSQ)
Fonds de la recherche en santé du Réseau SIDA et maladies infectieuses coordination
Québec (FRSQ)
Fonds de la recherche en santé du SIDAMI-Banque de spécimens viraux/Traitement des échantillons
Québec (FRSQ)
136,683
3,125
9,452
45,000
569
800
2,473
7,527
45,499
50,000
77,546
130,000
582
1,033
1,195
1,500
1,997
2,500
2,750
5,011
5,885
10,192
13,599
13,805
16,703
797
9,203
9,667
19,780
22,292
30,000
31,250
40,000
15
WAINBERG, Mark A.
WAINBERG, Mark A.
WAINBERG, Mark A.
WAINBERG, Mark A.
WAINBERG, Mark A.
WAINBERG, Mark A.
WAINBERG, Mark A.
WAINBERG, Mark A.
WARSHAWSKY, Paul
BALLARD, Stephanie
WILCHESKY, Machelle
WILCHESKY, Machelle
WILCHESKY, Machelle
Melnychuk, Luca
ZAHARATOS, Gerasimos
Industrial Contracts
AGULNIK, Jason
Québec (FRSQ)
Canada (IRSC)
Laboratoire de santé publique du
Québec
SIDAMI-Génotypage de la résistance au VIH.
47,000
What if HIV were unable to develop resistance against a new
therapeutic agent?
Phase 2 - Infrastructures pour la recherche sur l'infection au IVH: doter
le Québec et le Canada d'infrastructures pour un vaccin et des
thérapies contre le VIH et l'hépatite.
Genetic signatures and functional phenotypes implicated in HIV-1
transmission and drug resistance.
Viral and human genetic predictors of response to HIV therapies.
TanZamBo capacity building for HIV prevention research network.
61,424
Canada (IRSC)
Genome British Columbia
Centre de Recherches pour le
Développement International
(CRDI)
AIDS Research.
Instituts de recherche en santé du The Botswana-Canada AIDS vaccine discovery partnership.
Canada (IRSC)
Université McGill
Developing and testing innovative implementation strategies of and
integrated systematic pain assessment approach in the adult intensive
care unit
Centre Gériatrique Maimonides
Validation of the elder abuse suspicion index (EASI) in the geriatric longDonald Berman (Le)
term care setting.
Fonds de la recherche en santé du Non-pharmacological management of behavioral and psychological
Québec (FRSQ)
symptoms of dementia (BPSD) in long-term care: social determinants of
adherence to clinical guidelines
Instituts de recherche en santé du Prevention and Treatment of Neuropsychiatric Symptoms - Canadian
Canada (IRSC)
Consortium on Neurodegeneration in Aging (CCNA Team 11)
Instituts de recherche en santé du Highly stable trimerization of HIV-1 envelope based antigens will
Canada (IRSC)
improve their immunogenicity and capacity to elicit a neutralizing
antibody responses.
AGULNIK, Jason
Canada
Morphotek Inc
AGULNIK, Jason
Glaxo Wellcome Inc.
ASSOULINE, Sarit
Proteolix
ASSOULINE, Sarit
ARIAD Pharmaceuticals Inc.
ASSOULINE, Sarit
Glaxo Smith Kline
ASSOULINE, Sarit
Bristol-Myers Squibb Canada Inc.
ASSOULINE, Sarit
Glaxo Smith Kline
ASSOULINE, Sarit
Onyx Pharmaceuticals
ASSOULINE, Sarit
Bristol-Myers Squibb Canada
Inc.Novartis Pharma Canada Inc.
ASSOULINE, Sarit
Wyeth - Ayerst Canada Inc. (StLaurent, QC et North York, ON)
Treatment of metastatic EGFR wild type non-small cell lung cancer with
2nd or 3rd line erlotinib. A retrospective practice view.
A randomized double-blind, placebo-controlled, study of the safety and
efficacy of Farletuzumab in combination with a platinum containing
doublet in chemotherapy-naïve subjects with stage IV adenocarcinoma
of the lung.
A double-blind, randomized, placebo-controlled phase III study to
assess the efficacy of recMAGE-A3-A3+ antigen-specific cancer
immunotherapeutic as adjuvant therapy in patients with MAGE-A3positive non-small cell lung cancer.
CRU - An open-label, single-arm, phase 2 study of carfilzomib
maintenance therapy in subjects previously enrolled in carfilzomib
treatment protocols.
CRU - A pivotal phase 2 trial of Ponatinib (AP24534) in patients with
refractory chronic myeloid leukemia and ph+ acute lympnobastic
leukemia.
CRU - A three-part study of Eltrombopag in thrombocytopenic subjects
with myelodysplastic syndromes or acute myeloid leukemia (part 1:
open label, part 2: randomized, double-blind, part 3: extension.
CRU-A single-arm, open-label phase 2 study of Nivolumab (BMS936558) in subjects with relapsed or refractory follicular lymphoma (FL).
An extension study of eltrombopag olamine (SB-497115-GR) in adults,
with idiopathic thrombocytopenic purpura (ITP), previously enrolled in
an eltrombopag study.
CRU-An open-label single arm, phase I study of the pharmacokinetics
and safety of carfilzomib in subjects with relapsed multiple myeloma
and end-stage renal disease.
(Q-CROC-02) - A randomized phase II study of oral panobinostat
(LBH1589) with or without rituximab (the "Study Drug") to treat relapsed
or refractory B-cell non-Hodgkin lymphoma.
CRU - A phase 1/2 study of SKI-6-6 in Philadelphia chromosome
positive leukemias.
61,939
103,442
126,844
168,909
462,400
489,988
5,625
10,192
2,000
10,116
7,308
4,980
9,294
14,030
118
4,040
4,310
7,500
7,611
8,333
10,023
10,072
16
ASSOULINE, Sarit
Pharmacyclics
ASSOULINE, Sarit
Novartis Pharmaceuticals
Corporation
ASSOULINE, Sarit
Millennium Pharmaceuticals Inc
(Cambridge, MA, USA)
ASSOULINE, Sarit
Infinity Pharmaceuticals
ASSOULINE, Sarit
Genzyme Corp.
ASSOULINE, Sarit
AbbVie
ASSOULINE, Sarit
Canada
ASSOULINE, Sarit
Onyx Industries Inc.
ASSOULINE, Sarit
Canada
ASSOULINE, Sarit
Quintiles Inc. (USA)
ASSOULINE, Sarit
Genentech Inc..
ASSOULINE, Sarit
Canada
ASSOULINE, Sarit
ASSOULINE, Sarit
Gilead Sciences
ASSOULINE, Sarit
Medimmune Inc.
ASSOULINE, Sarit
Genentech Inc..
BARON, Murray
JSS Recherche médicale
BARON, Murray
Abbott Laboratories
BARON, Murray
Canada
BARON, Murray
Mount Sinai Hospital
BATIST, Gerald
Sunshine Biopharma Inc
CRU - A multicenter, open-label, phase 2, safety and efficacy study of
the Bruton's tyrosine kinase (Btk) inhibitor, pCI-32765, in subjects with
relapsed or refractory de Novo diffuse large B-cell lymphoma.
CRU-A phase II multi-center, open, label, randomized study to assess
safety and efficacy of two different schedules of oral LDE225 in adult
patients with relapsed/refractory or untreated elderly patients with acute
leukemia.
CRU - An open-label, dose-escalation, phase 1 study of MLN9708, a
second-generation proteasome inhibitor, in adult patients with
lymphoma.
CRU-A phase 2 study of IPI-145 in subjects with refractory indolent nonHodgkin lymphoma.
CRU - A phase 3, randomized, double-blind, placebo-controlled, multicenter study confirming the efficacy and safety of Genz-112638 in
patients with Gaucher Disease Type 1.
CRU - A phase 2 open-label study of efficacy of ABT-199 in subjects
with relapsed or refractory chronic lymphocytic leukemia harboring the
17p deletion.
CRU-An adaptive,comparative,randomized,parallel-group,multicenter,phase lb study of subcutaneous (SD) rituximab versus
intravenous rituximab both in combination with chemotherapy
(fludarabine and cyclophosphamide),in patients with previously
untreated...
CRU - A randomized, multicenter, phase 3 studycomparing carfilzomib,
lenalidomide, and dexamethasone (CRd) vs. lenalidomide and
dexamethasone (Rd) in subjects with relapsed multiple myeloma.
CRU-GO28852-A phase IB/II study, to evaluate the safety and efficacy
of vismodegib in relapsed/refractory acute myelogenous leukemia
(AML) and relapsed/refractory high-risk myeloldysplastic syndrome
(MDS).
CRU-A multicenter, phase III, open-label, randomized study in
relapsed/refractory patients with chronic lymphocytic leukemia to
evaluate the benefit of GDC-0199 (ABT-199) plus rituximab compared
with bendamustine plus rituximab.
CRU - A randomized, open-label, multicenter, phase II trial evaluating
the safety and activity of DCDT2980S in combination with rituximab or
DCDS4501A in combination with rituximab in patients with relapsed or
refractory B-cell non-Hodgkin's lymphoma.
CRU - A multi center, open-label, phase 1/1b study of escalating doses
of RO5503781 administered orally as a single agent or in combination
with cytarabine in patients with acute myelogenous leukemia (AML)
CRU-A single-arm, open-label, phase 2 study of Nivolumab (BMS936558) in subjects with relapsed or refractory diffuse large B-cell
lymphoma (DLBCL) after failure of autologous stem cell transplant
(ASCT) or after failure of at least two prior multi-agent
CRU-A Phase 2 open-label study evaluating the efficacy, safety,
tolerability, and pharmacodynamics of GS9973 in subjects with
relapsed or refractory hematologic malignancies.
CRU-A phase 2 open-label study of MEDI-551 and Bendamustine vs
Rituximab and Bendamustine in adults with relapsed or refractory CLL.
CRU-An open-label, multicenter, randomized, phase III study to
investigate the efficacy and safety of bendamustine compared with
bendamustine + RO5072759 (GA101) in patients with rituximabrefractory, indolent non-hodgkin's lymphoma.
A Canadian randomized controlled trial (RCT) of real world Cimzia
treatment in RA: Randomizing to stop vs continued DMARDs.
Real life evaluation of rheumatoid arthritis in Canadians taking
HUMIRA.
A Phase II/III, multicenter, randomized, double-blind, placebo-controlled
study to assess the efficacy and safety of tocilizumab versus placebo in
patients with systematic sclerosis.
The Canadian ArTHritis CoHort (CATCH): A prospective cohort study of
adults with new-onset inflammatory arthritis symptoms.
A biomarker-driven therapy in the age of personalized cancer medicine.
10,921
11,542
13,128
13,578
14,888
21,060
21,240
27,809
29,300
29,567
37,301
39,700
44,085
104,014
141,690
273,459
323
1,800
15,583
19,625
0
17
BATIST, Gerald
BLOSTEIN, Mark
BLOSTEIN, Mark
BLOSTEIN, Mark
CHERTKOW, Howard
CHERTKOW, Howard
CHERTKOW, Howard
COHEN, Albert
COHEN, Albert
COHEN, Albert
COHEN, Albert
COHEN, Victor
COHEN, Victor
COHEN, Victor
COHEN, Victor
COHEN, Victor
DASCAL, André
EISENBERG, Mark
FALLAVOLLITA, Sabrina
FALLAVOLLITA, Sabrina
AstraZeneca Canada Inc.
CRU-A phase I, open-label, multicenter study to assess the safety,
tolerability, pharmacokinetics and preliminary anti-tumour activity of
ascending doses of AZD5363 under adaptable dosing schedules in
patients with advanced solid malignancies.
Glaxo Smith Kline
Treatment of thromBocytopenia with EltRombopag or intrevenous
immune globulin (IVIG) before and DurING invasive procedures in
patients with immune thrombocytoPenia - BRIDGING ITP study.
ENOXA_L_02260-VTE Registry - National, prospective, observational
cohort study of venous thrombembolism management with the low
molecular weight heparin, enoxaparin, in the outpatient setting in
Canada.
Boehringer Ingelheim (Canada) Ltd A phase III, case series clinical study of the reversal of the
anticoagulant effects of dabigatran by intravenous administration of
5.0g idarucizumab (BI 655075) in patients treated with
dabigatranetexilate who have uncontrolled bleeding
Merck Frosst Canada Inc
A randomized, placebo controlled, parallel-group, double-blind efficacy
and safety trial of MK-8931 in subjects with mild to moderate
Alzheimer's disease.
Abbott Laboratories
A randomized, double-blind, placebo-controlled study to evaluate the
efficacy and safety of ABT-126 in subjects with mild-to-moderate
Alzheimer's Disease on stable doses of acetychloniesterase inhibitors.
TauRx Therapeutics Ltd.
Randomized, double-blind, placebo-controlled, parallel-group, 18-month
safety and efficacy study of leuco-methylthioninium
bis(hydromethanesulfonate) in subjects with mild Alzeimer's disease.
A 52 week randomised, double-blind, placebo-controlled study to
Robarts Research Institute
investigate the efficacy and safety of GSK1605786A in the maintenance
(formerly John P. Robarts
of remission in subjects with Crohn's disease.
Research Institute)
Abbott Laboratories
M10-223 - A multicenter, open-label study of the human anti-TNF
monoclonal antibody adalimumab to evaluate the long term safety and
tolerability of repeated administration of adalimumab in subjects with
ulcerative colitis.
An open-label extension study to assess the safety of GSK1605786A in
Robarts Research Institute
subjects with Crohn's disease.
(formerly John P. Robarts
Research Institute)
Quintiles Canada Inc.
A phase 3, open-label study to determine the long-term safety and
efficacy of MLN002 in patients with iulcerative colitis and Crohn's
disease.
Boehringer Ingelheim (Canada) Ltd An open label trial of afatinib in treatment-naive or chemotherapy pretreated patients with locally advanced or metastatic non-small cell lunch
cancer (NSCLC) harboring EGFR mutation(s).
Astellas Pharma Inc.
A randomized, double-blind, phase 2 study of erlotinib (Tarceva) in
combination with OSI-906 or placebo in chemonaive patients with
advanced NSCLC with activating mutations of the epidermal growth
factor receptor (EGFR) gene.
Pharmaceutical Research
A multi-center phase III randomized, double-blind placebo-controlled
Associates Inc.
study of the cancer vaccine Stimuvax (L-BLP25 or BLP25 liposome
vaccine) in non-small cell lung cancer (NSCLC) subjects with
unresectable stage III disease.
Poplar: A phase II, open-label, multicenter, randomized study to
Canada
investigate the efficacy and safety of MPDL3280A (ANTI-PD-L1
ANTIBODY) compared with docetaxel in patients with non-small cell
lung cancer after platinum failure.
OAK-A phase III, open-label, multicenter, randomized study to
Canada
investigate the efficacy and safety of MPDL3280A (Anti-PD-L1
antibody) compared with docetaxel in patients with non-small cell lung
cancer after failure with platinum-containing chemotherapy.
Medpace Inc.
A phase II, randomized, double-blind, active-controlled clinical study to
investigate the efficacy and safety of SMT19969 (200mg BID) for 10
days comparted with vancomycin (125mg QID) for 10 days for the
treament of
Pfizer Canada Inc.
GA3041Z4-Evaluation of Varenicline-(ChampixTM) in smoking
cessation for patients post-acute coronary syndrome (EVITA) trial.
Prospective observtional study to evaluate the use of musculoskeletal
ultrasonography to improve rheumatoid arthritis management:
Canadian experience (Echo Study).
Abbott Laboratories Ltd
Drug HUMIRA.
147,118
3,816
27,000
39,542
3,000
37,386
48,962
2,548
3,833
5,017
11,995
10,009
13,349
15,788
30,500
33,844
3,856
30,000
2,340
4,100
18
FERRARIO, Cristiano
Celldex Therapeutics
FERRARIO, Cristiano
FERRARIO, Cristiano
FERRARIO, Cristiano
Canada
Scimega Recherche
Sanofi Pasteur Inc. (USA)
GYGER, Martin
Celgene Corporation
GYGER, Martin
Celgene Corporation
GYGER, Martin
Celgene Corporation
HILZENRAT, Nir
HILZENRAT, Nir
HILZENRAT, Nir
HIRSCH, Andrew
HIRSCH, Andrew
HUDSON, Marie
HUDSON, Marie
KAHN, Susan Rebecca
KAHN, Susan Rebecca
KAHN, Susan Rebecca
KAHN, Susan Rebecca
A randomized multicenter pivotal study of CDX-011 (CRO11-vcMMAE)
in patients with metastatic, GPNMB over-expressing, triple-negative
breast cancer.
A phase II randomized, double-blind placebo controlled, study of
letrozole with or without BYL719 or buparlisib, for the neoadjuvant
treatment of postmenopausal women with hormone receptor-positive
HER2-negative breast cancer.
CRU - A phase II, multicenter, single-arm study of MDPL3280A in
patients with locally advanced or metastatic urothelial bladder cancer.
CRU - A phase 1b, open-label study to assess the safety and tolerability
of ONT-380 combined with ado-trastuzumab emtansine (T-DM1).
9,429
10,438
47,154
52,637
Efficacy, immunogenicity and safety study of clostridium difficile toxoid
vaccine in subjects at risk for C. difficile infection.
CRU-A phase 3, multicenter, randomized, open-label Study to Compare
the Efficacy and Safety of Pomalidomide in Combination with Low-Dose
Dexamethasone versus High-Dose Dexamethasone in Subjects with
Refractory or Relapsed and Refractory Multiple Myeloma.
84,265
CRU-Companion Study: Open-Label, Multi-Center, Single-Arm Study
for the Safety and Efficacy of Pomalidome (CC-4047) Monotherapy for
Subjects with Refractory or Relapsed and refractory Multiple Myeloma.
4,389
CRU-A multicenter, single-arm, open-label treatment use program for
pomalidomide (POM in combination with low dose dexamethasone (LdDex) in subjects with relapses or refractory multiple myeloma.
Janssen Pharmaceutica Inc
A Canadian retrospective registry to examine real world effectiveness,
safety, patient characteristics, and healthcare management across
various practice settings in HCV-infected patients who initiated
treatment with simeprevir.
Bristol-Myers Squibb Canada Inc. A phase 3 study with Asunaprevir and Declatasvir (DUAL) for null or
partial responders to peginterferon alfa-2a and ribavirin (P/R), intolerant
or ineligible to P/R subjects and treatment naive subjects with chronic
hepatitis C genotype 1b infection.
AbbVie
An international multicenter prospective observational study to evaluate
the epidemiology, humanistic and economic outcomes of treatment for
chronic hepatitis C virus (HCV) MOSAIC.
Bayer Canada Inc.
Long-term extension, multi-centre, multi-national study to evaluate the
safety and tolerability of oral BAY 63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5
mg tid) in patients with chronic thromboembolic pulmonary arterial
hypertension.
Bayer Canada Inc.
An open-label phase IIIb study of riociguat in patients with in-operable
CTEPH, or recurrent or persisting pulmonary hypertension (PH) after
surgical treatment who are not satisfactory treated and cannot
participate in any other CTEPH trial.
Prospective observational study to evaluate the use of musculoskeletal
ultrasonography to improve rheumatoid arthritis management:
Canadian experience (Echo Study).
Health-related quality of life (HRQol) across systematic autoimmune
rheumatic diseases (SARD).
Lawson Health Research Institute A prospective study of upper extremity deep vein thrombosis to
determine the prevalence of post-thrombotic syndrome in patients
managed with anticoagulation.
Bayer (Canada) Inc.
Reduced-dosed rivaroxaban and standard-dosed rivaroxaban versus
ASA in the long-term prevention of recurrent symptomatic venous
thromboemgolism (VTE) in patients with symptomatic deep-vein
thrombosis and/or pulmonary embolism (Study 16416).
Biomérieux Canada Inc.
REVERSE-REcurrent VEnous thromboembolism risk stratification
evaluation II: Validation of the "Men and HERD002" - A clinical decision
rule to identify patients with "Unprovoked" venous thromboembolism
who can discontinue anticoagulants after six months of
Daiichi Pharmaceutical Corporation A randomized, open-label, parallel-group, multi-center study for the
evaluation of efficacy & safety of edoxaban monotherapy versus (LMW)
heparin/warfarin in subjects with symptomatic deep-vein thrombosis edoxaban thrombus reduction imaging study (eTRIS
3,304
15,842
1,500
8,105
8,535
2,604
8,561
2,918
17,361
1,250
5,750
6,000
12,199
19
KAHN, Susan Rebecca
KARAPLIS, Andrew C.
KARAPLIS, Andrew C.
KARAPLIS, Andrew C.
KAVAN, Petr
Portola Pharmaceuticals, Inc.
(USA)
Multicenter, randomized, active-controlled efficacy and safety study
comparing extended duration betrixaban with standard of care
enoxaparin for the prevention of venous thromboembolism in acute
medically III patients.
Amgen Canada Inc (Mississauga, Prospective observational study to evaluate persistence with Prolia
Ont)
(denosumab) in postmenopausal women with osteoporosis in routine
clinical practice.
Eli Lilly Canada Inc.
Teriparatide and risedronate in the treatment of patients with severe
postmenopausal osteoporosis: Comparative effects on vertebral
fractures.
Amgen Canada Inc (Mississauga, A multi-center, international, randomized, double-blind, alendronateOnt)
controlled study to determine the efficacy and safety of AMG785 in the
treatment of postmenopausal women with osteoporosis.
Amgen Canada Inc (Mississauga, A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of
Ont)
Pegfilgrastim Administered to Subjects With Newly DX, LocallyAdvanced or Metastatic Colorectal Cancer Treated With Bevacizumab
and Either 5-Fluorouracil, Oxaliplatin, Leucovorin (Folfox) or
KAVAN, Petr
Genentech Inc..
KAVAN, Petr
Eisai Inc. (New Jersey)
KAVAN, Petr
Oncozyme Pharma Inc.
KAVAN, Petr
KAVAN, Petr
KAVAN, Petr
KAVAN, Petr
KAVAN, Petr
KAVAN, Petr
KAVAN, Petr
LANGLEBEN, David
LANGLEBEN, David
LANGLEBEN, David
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase II
Study Evaluating the Efficacy and Safety of Onartuzuabm (MetMab) in
Combination with Bevacizumab or Onartuzumab Monotherapy in
Patients with Recurrent Glioblastoma
A Multicenter, Randomized, Open-Label, Phase 3 Trial toCompare the
Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line
Treatment of Subjects With Unresectable Hepatocellular Carcinoma
CRU - A phase II clinical study using Pentamidine in patients with
metastatic cancer undergoing standard chemotherapy (mFOLFOX6 or
FOLFIRI) as second-line treatment.
A Randomised Phase III Study of Capecitabine or 5-Fluorouracil-Based
Regimen with or without Oxaliplatin as 2nd Line Treatment of Advanced
or Metastatic Pancreatic Cancer in Patients Who Have received
Gemcitabine-Based Chemotherapy
A randomized, phase III, multicenter, double-blind, placebo-controlled
Canada
study evaluating the efficacy and safety of onartuzumab (metmab) in
combination with 5-fluorouracil, folinic acid, and oxaliplatin
(MFOLFOX6) in patients with metastatic HER2-negative,
CRU - A phase Ib/II multi-center, open-label, dose escalation study of
Inc.Novartis Pharma Canada Inc. LGX818 and cetuximab or LGX818, BYL719, and cetuximab in patients
with BRAF mutant metastatic colorectal cancer.
Amgen Canada Inc (Mississauga, A retrospective observational study to estimate the attrition of patients
Ont)
across lines of systemic treatment for metastatic colorectal cancer in
Canada.
Boehringer Ingelheim (Canada) Ltd A double-blind, randomized, placebo controlled phase III study of
nintedanib plus best supportive care (BSC) versus placebo plus BSC in
patients with metastatic colorectal cancer refrectory to standard
therapies
Boehringer Ingelheim (Canada) Ltd BIBW 2992 WITH OR WITHOUT DAtLY TEMOZOLOMIDE IN THE
TREATMENT OF PATIENTS WITH RECURRENT MALIGNANT
GLIOMA
A Multicenter, Single arm, Open Label Clinical Trial to Evaluate the
Safety and Health-Related Quality of Life of Aflibercept in Patients with
Metastatic Colorectal Cancer (mCRC) Previously Treated with an
Oxaliplatin-Containing Regimen, McG1308
Actelion Pharmaceuticals Canada A prospective, multicenter, double-blind, randomized, placeboInc.
controlled, parallel-group, 12-week study to evaluate the safety and
tolerability of macitentan in subjects with combined pre-and postcapillary pulmonary hypertention (CpcPH) due to left
Bayer Canada Inc.
An open-label phase IIIb study of riociguat in patients with in-operable
CTEPH, or recurrent or persisting pulmonary hypertension (PH) after
surgical treatment who are not satisfactory treated and cannot
participate in any other CTEPH trial.
Actelion Pharmaceuticals Canada AC-065A303: Long-term single-arm open-label study, to assess the
Inc.
safety and tolerability of Act-293987 in patients with pulmonary arterial
hypertension.
45,484
3,546
10,172
24,218
191
549
1,097
1,891
1,964
2,848
3,127
3,260
4,089
6,005
17,040
5,800
9,218
9,802
20
LANGLEBEN, David
LANGLEBEN, David
LONGTIN, Yves
MICHEL, Caroline
MICHEL, Caroline
MILLER, Mark A.
MILLER, Mark A.
MILLER, Wilson
MILLER, Wilson
MILLER, Wilson
MILLER, Wilson
MILLER, Wilson
MILLER, Wilson
MILLER, Wilson
MILLER, Wilson
MILLER, Wilson
MILLER, Wilson
MILLER, Wilson
MILLER, Wilson
MILLER, Wilson
MILLER, Wilson
Actelion Pharmaceuticals Canada
Inc.
A multicenter, double-blind placebo-controlled phase 3 study to
demonstrate the efficacy and safety of ACT-293987 in patients with
pulmonary arterial hypertension.
Institut de Cardiologie de Montréal Phase-II study of the use of PulmoBind for molecular imaging of
(ICM)
pulmonary hypertension.
Agence de santé publique du
Vancomycin-resistant enterocci (VRE) occurrence report protocol
Canada (ASPC)
Canadian nonsocomial infection surveillance program (CNISP).
Bayer Canada Inc.
A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the hemodynamic effects of riociguat (BAY 632521) as well as study & kinetics in patients with pulmonary
hypertension associated with left ventricular...
Aventis Pharma
Heart failure clinic equipment donation.
A phase III, randomized, double-blind, placebo-controlled, adaptive
design study of the efficacy, safety, and tolerability of a single infusion
of MK-3415 (human monoclonal antibody to Clostridium difficile toxin
A),
A phase III, double-blind, randomized, placebo-controlled, multicenter
clinical trial to study the safety, tolerability, efficacy , and
immunogenicity of V212 in recipients of autologous hematopoietic cell
transplants (HCTs).
MethylGene Inc.
CRU - Open-label dose-escalation trial to evaluate the safety,
pharmacokinetics, and pharmacodynamics of daily oral MGCD265
administered without interruption to subjects with advanced
malignancies.
Glaxo Smith Kline
CRU - VEG108844 - A study of Pazopanib versus Sunitinib in the
treatment of subjects with locally advanced and/or metastatic rena cell
carcinoma.
CRU - A multi-center, open-label, first-in-human, phase I doseCanada
escalation study of single agent RO5503781, a small molecule MDM2
antagonist, administered orally in patients with advanced malignancies,
except leukemia. Protcol no NP27872.
Glaxo Smith Kline
CRU - A rollover study to provide continued treatment with
GSK2118436 to subjects with BRAF mutation-positive tumors.
Astellas Pharma Canada, Inc.
CRU - A phase I, open-label, multi-center study to assess the safety,
pharmacokinetics and effectiveness of AGS-116C3F monotherapy in
subjects with renal cell carcinoma of clear cell or papillary histology.
Amgen Canada Inc (Mississauga, CRU-A phase 2, multicenter, single-arm trial to evaluate the
Ont)
biodistribution and shedding of talimogene laherparepvec in subjects
with inresected, stage IIIb to IVM1a melanoma.
Bristol-Myers Squibb Canada Inc. CRU - A randomized, open-label, phase 3 study of BMS-936558 vs.
everolimus in subjects with advanced or metastic clear-cell renal cell
carcinoma who have received prior anti-angiogenic therapy.
Medpace Inc.
CRU - An international phase 3 randomized trial of autologous dendritic
cell immunotherapy (AGS 003) plis standard treatment of advanced
renal cell carcinoma (ADAPT).
Glaxo Smith Kline
CRU - BRF113683: a phase III randomized, ope-label study comparing
GSK2118436 to DTIC in previously untreated subjects with BRAF
mutation positive advanced (stage III) or metastatic (stage IV)
melanoma.
CRU - A phase Ib/II, multicenter, study of LEE011 in combination with
Corporation
lgx818 in adult patients with BRAF mutant melanoma.
CRU-CLGX818X2109 - The LOGIC 2 Trial - A phase II, multi-center,
Corporation
open-label study of sequential LGX818/MEK162 combination followed
by a rational combination with targeted agents after progression, to
overcome resistance in adult patients with locally
CRU-A multiple-center, open-label clinical pharmacology study with
Canada
RO5503781 an MDM2 antagonist, in patients with solid tumors to
determine: Part 1- One-sequence, 2-period crossover design to
investigate the effect of posaconazole, a strong CYP3A4 inhibit
Bristol-Myers Squibb Canada Inc. CRU - CA209-037: A randomized, open-label phase III trial of BMS936558 versus investigator's choice in advanced (unresectable or
metastic) melanoma patients progressing post anti-CTLA-4b therapy.
CRU - A phase Ib/II, multicenter, open-label, dose escalation study of
Inc.Novartis Pharma Canada Inc. LGX818 in combination with MEK162 in adult patients with BRAF V600 dependent advanced solid tumors.
11,000
60,500
34,395
22,547
153,000
1,322
6,629
2
860
1,500
2,800
4,868
7,050
8,668
12,526
14,891
36,208
58,426
111,500
137,120
229,917
21
MILLER, Wilson
OUGHTON, Matthew
POLLAK, Michael
IntelligentMDx (IMDx)
Teva Pharma Industries CDA
POLLAK, Michael
Hanall Biopharma
RICHARDS, Brent
RICHARDS, Brent
RICHARDS, Brent
RUDSKI, Lawrence
King's College London
Glaxo Smith Kline
Eli Lilly Canada Inc.
Canadian Heart Research Center
RUDSKI, Lawrence
Genzyme Canada
SCHIFFRIN, Ernesto
Institut Servier (L') (France)
Immunotec Recherche
SHEPPARD, Richard
SHEPPARD, Richard
SHEPPARD, Richard
bioMérieux sa (France)
SHEPPARD, Richard
Bayer Canada Inc.
SIRHAN, Shireen
YM BioSciences Inc.
SIRHAN, Shireen
INC Research
SIRHAN, Shireen
SIRHAN, Shireen
Gilead Sciences
SIRHAN, Shireen
Gilead Sciences
THERRIEN, Judith
Hamilton Health Sciences
TRIFIRO, Mark A
TRIFIRO, Mark A
Genome Prairie
CRU-A multicenter, randomized, controlled, three-arm, phase III study
to evaluate the safety and efficacy of two dosing schedules of MK-3475
compared to ipilimumab in patients with advanced melanoma.
Contract for the selection of clinical specimens.
CRU - A randomized phase 3 comparing standard first-line
Docetaxel/Prednisone to Docetaxe/Prednisone in combination with
Custirsen (OGX-011) in men with metastatic castrate resistant prostate
cancer.
The study involves in vitro and in vivo assays and no human
participants are to be in invloved in the study and characterization of
novel biguanides.
Standard operating procedures.
Repisitioning existing therapies to new diseases.
Collaborative Agreement.
Acute coronary syndromes quality enhancement research initiative III.
ACS III QuERI.
Prevalence of Anderson-fabry disease (AFD) in multiple high risk
populations in a single hospital-based setting.
Gene expression profile in small resistance arteries in patients with
hypertension with or without nephroangiosclerosis and its relation to
small and large artery function and remodeling.
Immunocal Prophylaxis in the GFAP.HMOX1 mouse model of
neurodevelopmental and neurodegenerative disorders - Phase 1 and
Phase 2.
A multicenter, randomized, double-blind, parallel-group, activecontrolled study to evaluate the efficacy and safety of LCZ696
compared to enalapril on morbidity and mortality in patients with chronic
heart failure and reduced injection fraction.
A randomized, double-blind, event-driven, multicenter study comparing
the efficacy and safety of oral Rivaroxaban with placebo for reducing
the risk of death, myocardial infarction or stroke in subjects with chronic
heart failure and significant coronary
Galectin-3 as an early and sensitive marker for anthracyclines (with or
without Trastuzumab) and Tyrosine kinase inhibitor induced
cardiotoxicity
A randomized, double-blind, double-dummy, multi-center study to
assess safety and efficacy of BAY-94-8862 in subjects with emergency
presentation at the hospital because of worsening chronic heart failure
with left ventribular systolic dysfunction and
CRU - A phase II, open-label extension study evaluating the long-term
safety, tolerability and efficacy of orally-administered CYT387 in primary
myelofibrosis or post-polycythemia vera or post-essential
thrombocythemia myelofibrosis (CCL09101E).
CRU - An open-label, multiple simon 2-stage study of INCB039110
administered orally to subjects with primary myelofibrosis (PMF), post
polycythemia vera-myelofibrosis (PPVMF) or post essential
thrombocythemia-myelofibrosis (PET-MF).
CRU-ARD12042-A randomized phase II, open-label study of the
efficacy and safety of orally administered SAR302503 in patients with
polycythemia vera (PV) or essential thrombocythemia (ET) who are
resistant or intolerant to hydroxyurea.
CRU-A phase 2, open-label, randomized study to evaluate the safety
and efficacy of momelotinib in subjects with plycythemia vera or
essential thrombocythemia.
CRU-Open-label study to assess the long-term safety and efficacy of
momelotinib in subjects with primary myelofibrosis, post-polycythemia
vera myelofibrosis, post-essential thrombocythemia myelofibrosis,
polycythemia vera or essential thrombocythemi.
BAV - Beta-blockers and angiotensin receptor blockers in bicuspid
aortic valve aortopahy.
A double-blind placebo-controlled, randomized, two stage, parallelgroup, adaptive design phase 2a study to evaluate the effects of BMS813160 in subjects with type 2 diabetes mellitus
Total utilization flax genomics (TUFGEN).
462,907
7,510
11,038
30,000
8,307
48,323
111,610
2,000
19,245
314,978
47,617
2,425
4,000
17,038
44,448
2,422
7,302
9,705
9,800
29,926
7,465
10,300
15,000
22
VAITEKUNAS, Susan
Servier Canada Inc
WAINBERG, Mark A.
Merck Sharp & Dohme Research
Laboratory
Clinical Research Awards
Chen-Tournoux, A
Department of Medicine, JGH
Cohen, A
Dascal, A
Galiatsatos, P
Greenaway, C.
Joyal, D
Langleben, D
Levinoff, E.
Palayew, M.
Roshdy, O.
Rudski, L.
Saad, N.
Schweitzer, M.
Sebag, I
Szilagyi, A.
Tagalakis, V.
Tamilia, M
Teltscher, M.
Therrien, J
Wyse, J.
TOTALS
251
Efficacy and safety of 3 doses of S 38093(2,5 and 20 mg/day) versus
placebo in co-administration with donepezil (10 mg/day) in patients with
moderate Alzheimer's Disease. A 24-week international, multi-centre,
randomised, double-blind, placebo-controlled
Part 1: Impact of subtype-specific variability on hte effectiveness of
integrase inhibitor.
158,008
Echocardiographic quantification of epicardial fat and its implications for
cardiovascular risk
Inflammatory bowel disease rapid access clinic
Microbiome Replenishment Strategies to Treat and Protect against C
difficile
Impact of Lynch syndrome on career pursuits, professional
development, and academic studies
The Burden of Viral Hepatitis in Migrants: A Population based Study
Novel techniques in chronic total occlusions (CTO) recanalization
Assessment of recruitment of functional pulmonary microvascular
surface area in the determination of exercise limitation in patients with
pulmonary arterial hypertension
Cognitive Impairment and Post-operative Outcomes in Elderly
Individuals
The Airways Centre at the Jewish General Hospital: Aspects of care in
COPD patients
Analysis of the direct growth inhibitory effect of ipilimumab on
melanoma cells
Echocardiography-based research on the right heart
Chronic Obstructive Pulmonary Disease (Copd) and Pulmonary
Rehabilitation
Niemann-Pick C1-like (NPC1L1) structure/function analysis in a family
of disparate ezetimibe responders
Matrix-array imaging for real-time, three-dimensional echocardiography
and evolving techniques in cardiac mechanics
IBD Epidemiology: Relationships with Vitamin D and population lactase
distributions
Venous thrombosis: Epidemiology and Cancer
The role of oncogenic and epigenic events in the prediction of
invasiveness and aggressiveness of differentiated thyroid carcinoma
Fecal Microbiota Transplant for the Treatment of C Difficile Infection
Beta Blockers and Angiotensin Receptor Blockers in Bicuspid Aortic
Valve Disease Aortopathy
The value of Botox-A in Acute Radiation Proctitis
12,000
12,000
4,000
12,000
12,000
12,000
12,000
8,000
4,000
4,000
12,000
8,000
12,000
12,000
4,000
12,000
12,000
8,000
12,000
27,568,152
2,927,850
4,000
188,000
4,174,821
23

research grants 2014-2015

Transcription

Documents pareils

So much data, so little time

guide de préparation du CV commun

FORMULAIRE DE RENONCIATION AU DROIT À L`IMAGE ______

The clubs` funding forms for the 2016-2017 school year - LSA

Résultat du programme d`embauche d`un étudiant d`été 2016

PDF - Traumatisme crânien léger / Commotion cérébrale

Department of Sociology Faculty of Arts Département de sociologie

IRSC - Faculté de communication